ULTRASONICALLY-ENHANCED CONTINUOUS AND LARGE-SCALE PRODUCTION METHOD FOR NANO-FORMULATIONS

Abstract

Disclosed is an ultrasonically-enhanced continuous and large-scale production method for nano-formulations. Specifically disclosed is a preparation system for continuous production of nano-formulations, comprising (a) a first pipe, (b) a second pipe, (f) an ultrasonic device, (c) a combined pipe and (e) a (fluid) outlet thereof. The first pipe and the second pipe are connected to the combined pipe. A first phase solution enters the combined pipe through a first pipe outlet, and a second phase solution enters the combined pipe through a second pipe outlet. The ultrasonic device acts on the part or the whole of the combined pipe. The first phase solution and the second phase solution are turbulently mixed in the combined pipe to form a combined phase, and flow out through the outlet of the combined pipe.

Claims

1. A production system, which includes (a) a first pipeline, (b) a second pipeline, (f) an ultrasonic device, (c) a combined pipeline and (e) a (fluid) outlet; wherein, the first pipeline and the second pipeline are connected to the combined pipeline, the first pipeline is coaxial with the combined pipeline and the second pipeline is perpendicular to the combined pipeline; the first pipeline outlet is positioned within the combined pipeline; the first phase solution enters the combined pipeline through the first pipeline outlet, the second phase solution enters the combined pipeline through the second pipeline outlet; the ultrasonic device acts on part or the whole of combined pipeline; the first phase solution and the second phase solution are mixed in the combined pipeline to form a combined phase; the combined phase flows out through the outlet of the combined pipeline.

2. The system of claim 1, wherein: (1) the core part of the production system includes: (a) a first pipeline; (b) a second pipeline; (c) a combined pipeline; (d) turbulent mixing device; (e) fluid outlet; (f) ultrasound devices with adjustable power; wherein, the first pipeline and the second pipeline are connected to the combined pipeline, the first phase solution enters the combined pipeline through the first pipeline outlet, the second phase solution enters the combined pipeline through the second pipeline outlet, the first phase solution and the second phase solution are mixed in the combined pipeline to form a combined phase; the power adjustable ultrasonic device acts on part or the whole of combined pipeline; the combined phase is fully mixed by a turbulent mixing device; after the mixing, the nanoparticles are collected into a suitable container through the outlet of the combined pipeline; (2) the mixing process of the first phase solution and the second phase solution is carried out under ultrasonication; (3) the nano-formulations are polymeric nanomicelles, nanoliposomes, lipid nanoparticles or small molecule nanoparticle assemblies.

3. The system of claim 1, wherein the production system fulfills one or more of the following: (1) the nano-formulations are selected from one or more of polymeric nanomicelles, polymer nanoparticles, nanoliposomes, lipid nanoparticles and small molecule nanoparticle assemblies; (2) the first pipeline outlet is a spray hole with a certain shape and diameter, and the first phase solution passes through the first pipeline and enters the combined pipeline through the spray hole.

4. The system of claim 1, wherein the production system fulfills one or more of the following: (1) the combined pipeline length is selected from 6 to 120 cm, such as 9 cm or 36 cm; (2) the ratio of the combined pipeline length to the combined pipeline inner diameter is (16-450): 1, such as 16.7:1, 30:1 or 450:1; (3) the first pipeline outer diameter D1(O) is 0.35 to 2 mm, such as 0.35 mm, 1 mm or 2 mm; (4) the spray hole diameter D1(S) at the end of first pipeline is selected from 0.03-5.0 mm; preferably 0.2 to 0.6 mm, such as 0.2 mm, 0.25 mm, 0.3 mm, 0.4 mm or 0.6 mm; (5) the second pipeline outer diameter D2(O) is 6 mm; (6) the second pipeline inner diameter D2(IN) is selected from 0.3-50.0 mm; preferably 0.8 to 5.4 mm, such as 0.8 mm, 3.0 mm or 5.4 mm; (7) the combined pipeline outer diameter D3(O) is 6 mm; (8) the combined pipeline inner diameter D3(IN) is selected from 0.03-5.0 mm; preferably 0.8 to 5.4 mm, such as 0.8 mm, 3.0 mm or 5.4 mm; (9) the second pipeline inner diameter D2(IN) is the same as the combined pipeline inner diameter D3(IN); (10) the ratio of the spray hole diameter D1(S) at the end of first pipeline to the combined pipeline inner diameter D3(IN) can be 1:(2-50), such as 1:3.2, 1:7.5, 1:9 or 1:18; (11) the mixing is turbulent mixing; the turbulent mixing can be achieved by adding a turbulent mixing device in the combined pipeline; there can be one or more turbulent mixing devices; (12) the ultrasonic devices are ultrasound devices with adjustable power.

5. The system of claim 4, wherein the production system fulfills one or more of the following: (1) the materials used in the first pipeline, the second pipeline, the combined pipeline, the turbulent mixing device, and the fluid outlet are each selected from one or more of stainless steel, polytetrafluoroethylene, polyethylene, polypropylene, latex, silicone, or other polymer materials; (2) the turbulent mixing achieved by turbulent mixing device includes: (a) increasing the fluid flow velocity; (b) changing the degree of pipeline twisting; (c) adding baffles or specialized objects within the pipeline, such as a static mixer; the Reynolds number calculated based on the fluid in the circular tube is selected from 500-100000; (3) the turbulent mixing device is a device that mixes the first phase solution and the second phase solution to reach a turbulent flow state, such as a static mixer; the static mixer can be selected from one or more of SV type static mixer, SX type static mixer, SL type static mixer, SH type static mixer and SK type static mixer, preferably SK type static mixer; (4) the quantity of flow Q1 of the first phase solution through the first pipeline is selected from 1-1000 ml/min; the temperature t1 of the first phase solution is selected from 0-90 C.; the quantity of flow Q2 of the second phase solution through the second pipeline is selected from 10-10000 ml/min; the temperature t2 of the second phase solution is selected from 0-90 C.; (5) the ultrasonic frequency of the power adjustable ultrasonic device is 15 kHz-1.0 MHz, preferably 15 kHz-40 kHz, more preferably 19 kHz-40 kHz; the ultrasonic power range is 0.1-20 kW, preferably 100-1000 W.

6. The system of claim 1, wherein the production system fulfills one or more of the following: (1) the polymeric nanomicelle component is selected from an amphiphilic polymer and an antitumor drug; the amphiphilic polymer is selected from PEG-PLA, PEG-PCL, PEG-linker-PLA or PEG-linker-PCL, wherein, the linker is a linker selected from C1-C30 small molecule fragment; and the number average molecular weight of PEG is 400-20000 polyethylene glycol segments or mono-protected polyethylene glycol segments; (2) the nanoliposomes are blank liposomes without drug encapsulation or liposomes with drug encapsulation; (3) the lipid nanoparticles are lipid nanoparticles encapsulating antitumor drugs; (4) the small molecule nanoassemblies are selected from antitumor drug/photosensitizer nanoassemblies, antitumor drug/antitumor drug nanoassemblies, antitumor drug/other drug (e.g., curcumin) nanoassemblies, antitumor drug/excipient (e.g., amphiphilic polymer PEG-PLA, DSPE-PEG or PLGA polymer) nanoassemblies, two or more drug nanoassemblies (e.g., SN38 and irinotecan), or small molecule drug/excipient nanoassemblies.

7. The system of claim 6, wherein the production system fulfills one or more of the following: (1) the antitumor drug is selected from one or more of abemaciclib, abiraterone, abrocitinib, acalabrutinib, afatinib, aldesleukin, alectinib, alflutinib, almonertinib, altretamine, amcenestrant, aminoglutethimide, amsacrine, anastrozole, anlotinib, apalutamide, apatinib, arzoxifene, asciminib, asparaginase, avapritinib, avitinib, axitinib, azacitidine, baricitinib, belinostat, bendamustine, bexarotene, bicalutamide, bicyclol, binimetinib, bleomycin, boanmycin, bortezomib, bosutinib, brigatinib, buserelin, busulfan, cabazitaxel, cabozantinib, calaspargase, calicheamycin, capecitabine, capmatinib, carboplatin, carfilzomib, carmustine, carmofur, cedazuidine, ceritinib, cetrorelix, chidamide, chlorambucil, cisplatin, cladribine, clofarabine, cobimetinib, colchicine, copanlisib, crizotinib, cyclophosphamide, cytarabine, dabrafenib, dacarbazine, dacomitinib, dactinomycin, dalpiciclib, darolutamide, dasatinib, daunorubicin, decitabine, degarelix, delgociclib, denileukin, deruxtecan, docetaxel, donafenib, doxorubicin, duvelisib, enasidenib, encorafenib, ensartinib, entrectinib, enzalutamide, enzastaurin, elacestrant, epirubicin, erdafitinib, eribulin, erlotinib, estradiol, estramustine, etoposide, everolimus, exemestane, fasudil, fedatinib, filgotinib, floxuridine, fludarabine, flumatinib, fluorouracil, flutamide, fluzoparib, formestane, fostamatinib, fruquintinib, fulvestrant, gefitinib, gemcitabine, gilteritinib, giredestrant, glasdegib, goserelin, histrelin, hydroxyurea, ibrutinib, ibudilast, icaritin, icotinib, idarubicin, idelalisib, ifosfamide, imatinib, imiquimod, infigratinib, ingenol mebutate, interferon alfa-2b, irinotecan, ivosidenib, ixabepilone, ixazomib, lanreotide, lapatinib, larotrectinib, lenalidomide, lenvatinib, letrozole, leucovorin, leuprolide, lomustine, lonafarnib, lorlatinib, lurbinctedin, maytansine, mechlorethamine, medroxyprogesterone, megestrol, melphalan, melphlan flufenamide, mercaptopurine, methotrexate, methoxsalen, methylprednisolone, midostaurin, mitomycin, mitotane, mitoxantrone, mitozolomide, mobocertinib, monomethylauristatin E, monomethylauristatin F, nelarabine, nandrolone, neratinib, nearsudil, nilotinib, nilutamide, nintedanib, niraparib, octreotide, olaparib, olmutinib, omacetaxine, orelabrutinib, osimertinib, oxaliplatin, paclitaxel, pacritinib, palbociclib, pamidronate, pamiparib, panobinostat, pazopanib, peficitinib, pegaptanib, pegaspargase, peginteferon alfa-2b, pemigatinib, pemetrexed, pentetreotide, pentostatin, pexidartinib, phenoxybenzamine, pidotimod, plinabulin, plitidepsin, pomalidomide, ponatinib, porfimer, pralatrexate, pralsetinib, prednisolone, procarbazine, pyrotinib, quizartinib, radotinib, raloxifene, raltitrexed, regorafenib, ribociclib, rintatolimod, ripretinib, romidepsin, rucaparib, ruxolitinib, savolitinib, selinexor, selpercatinib, selumetinib, sonidegib, sorafenib, sotorasib, streptozocin, sunitinib, surufatinib, talazoparib, tamoxifen, tazemetostat, tegafur, temozolomide, temsirolimus, teniposide, tepotinib, teprenone, thalidomide, thioguanine, thiotepa, thyrotropin alfa, tipiracil, tipifarnib, tirabrutinib, tirbanibulin, tivozanib, trametinib, tofacitinib, topotecan, toremifene, trabectedin, tretinoin, trifluride, trilaciclib, triptorelin, tucatinib, upadacitinib, umbralisib, utidelone, uroacitide, valrubicin, vandetanib, vemurafenib, venetoclax, vinblastine, vincristine, vindesine, vinflunine, vinorelbine, vismodegib, vorinostat, zanubrutinib, zoledronic acid, amatoxins, anthacyclines, anthracenes, anthramycins, auristatins, bryostatins, camptothecins, carmaphycins, combretastatins, cyclosporines, cryptomycins, ecteinascidins, ellipticenes, esperamicins, mustines, neothramycins, ozogamicins, phenoxazines, podophyllotoxins, pyrrolobenzodiazepines, sibiromycins, thailanstatins, tomamycns, tubulysins, taxanes, vinca alkaloids, 7-epipaclitaxel, 2-acetylpaclitaxel, 10-deacetylpaclitaxel, 7-epi-10-deacetyltaxol, 7-xylosyltaxol, 10-deacetyl-7-glutarylpaclitaxel, 7-N,N-dimethylglycylpaclitaxel, 7-L-alanylacetaxel, larotaxel, camptothecin, 9-aminocamptothecin, 9-nitrocamptothecin, lurtotecan, gimatecan, belotecan, 10-hydroxycamptothecin, 10-hydroxy-7-ethyl-camptothecin (SN-38), exatecan, pirarubicin, aclacinomycin, sirolimus, tacrolimus, progesterone, estrogen, rapamycin, mithramycin, harringtonine or curcumin; the antitumor drug is preferably selected from one or more of camptothecin, 9-aminocamptothecin, 9-nitrocamptothecin, lurtotecan, gimatecan, belotecan, 10-hydroxycamptothecin, 10-hydroxy-7-ethyl-camptothecin (SN-38), exatecan, topotecan, deruxtecan, paclitaxel, docetaxel, cabazitaxel, 7-epipaclitaxel, 2-acetylpaclitaxel, 10-deacetylpaclitaxel, 7-epi-10-deacetyltaxol, 7-xylosyltaxol, 10-deacetyl-7-glutarylpaclitaxel, 7-N,N-dimethylglycylpaclitaxel, 7-L-alanylacetaxel, larotaxel, doxorubicin, epirubicin, daunorubicin, pirarubicin, aclacinomycin, etoposide, teniposide, vinblastine, vincristine, vinorelbine, vindesine, maytansine, curcumin, harringtonine, homoharringtonine, gemcitabine, capecitabine, fludarabine, cladribine, pemetrexed, bortezomib, carfilzomib, ixazomib, carmustine, fluorouracil, cytarabine, cyclosporine A, eribulin, trabectedin, gefitinib, erlotinib, lapatinib, afatinib, dacomitinib, vandetanib, neratinib, osimertinib, imatinib, sorafenib, sunitinib, lapatinib, dasatinib, olaparib, niraparib, rucaparib, fluzoparib, pamiparib, veliparib, talazoparib, apatinib, palbociclib, abemaciclib, ribociclib; (2) the photosensitizers include cyanine molecules, porphyrin molecules, porphyrin precursors, phthalocyanine molecules and chlorin molecules; wherein, the cyanine molecules are preferably selected from one or more of indocyanine green (IR780), new indocyanine green (IR820), indocyanine green and indocyanine green analogs; the porphyrin molecule is preferably selected from hematoporphyrin monomethyl ether; the porphyrin precursor is preferably selected from one of 5-aminolevulinic acid and 5-aminolevulinic acid esters; the phthalocyanine molecule is preferably selected from one or more of copper phthalocyanine, cobalt phthalocyanine, aluminum phthalocyanine, nickel phthalocyanine, calcium phthalocyanine, sodium phthalocyanine, magnesium phthalocyanine, zinc phthalocyanine, indium phthalocyanine, oxytitanium phthalocyanine, manganese phthalocyanine or phthalocyanine derivatives; the chlorin molecules are preferably selected from one or more of chlorins, talaporfin, verteporfin, temoporfin, rostaporfin, porfimer sodium, hemoporfin and HPPH.

8. The system of claim 3, wherein the production system fulfills one or more of the following: (1) the polymeric nanomicelles are PTX/PEG-PLA polymeric micelles or PTX/PEG-Phe-PLA polymeric micelles; (2) the nanoliposomes are HSPC/CHOL/DSPE-PEG blank liposomes or PTX/HSPC/CHOL/DSPE-PEG liposomes; wherein, the molar ratio of HSPC/CHOL/DSPE-PEG is 56:38:5 or 89:57:4; (3) the lipid nanoparticle is a PolyI lipid nanoparticle, such as Poly I/ALC-0315/DSPE-PEG2000/HSPC/cholesterol; (4) the polymer nanoparticles are PEG-PLA polymer nanoparticles, PLGA polymer nanoparticles or PTX/PLGA polymer nanoparticles; (5) the small molecule nanoassembly is an anti-tumor drug/photosensitizer nanoassembly, preferably SN-38/ICG nanoparticles, PTX/ICG nanoparticles, curcumin/CPT11 nanoparticles or SN-38/CPT11 nanoparticles.

9. A production method for producing nano-formulations, which includes the following steps: in the system of claim 1, the first phase solution and the second phase solution are mixed under ultrasonication, nano-formulations are collected from combined phase through the fluid outlet; A. when the nano-formulations are polymeric nanomicelles, the solvent in the first phase solution is a good solvent for an anti-tumor drug or its pharmaceutically acceptable salt, and the solute is (1) the anti-tumor drug or its pharmaceutically acceptable salt, or (2) the anti-tumor drug or its pharmacologically acceptable salt and polymer; the solvent in the second phase solution is an anti-solvent of the anti-tumor drug or its pharmaceutically acceptable salt, and the solute is (1) absent, or (2) polymer; then the solute in the first phase solution is an anti-tumor drug or its pharmaceutically acceptable salt and polymer, the solute in the second phase solution does not exist; when the solute in the first phase solution is an anti-tumor drug or its pharmaceutically acceptable salt, the solute in the second phase solution is polymer; B. when the nano-formulations are polymer nanoparticles, the solvent of the first phase solution is a good solvent for the polymer, and the solute is (1) polymer, or (2) polymer and anti-tumor drug; the second phase solution is water or water containing 0.5% PVA; C. then the nano-formulations are nanoliposomes, the solvent of the first phase solution is a good solvent for the lipid component, and the solute is (1) the lipid component of the liposome, or (2) the lipid component of the liposome and the anti-tumor drug; the second phase solution is water or aqueous buffer solution with a certain pH value and a certain osmotic pressure; D. when the nano-formulations are lipid nanoparticles, the solvent of the first phase solution is a good solvent for the lipid component, and the solute is the lipid component of the lipid nanoparticle; the solvent of the second phase solution is aqueous buffer solution with a certain pH value and a certain osmotic pressure; the solute is anti-tumor drug; E. when the nano-formulations are anti-tumor drug/photosensitizer nanoassembly, the solvent in the first-phase solution is a good solvent of the anti-tumor drug or its pharmaceutically acceptable salt, and the solute is (1) the anti-tumor drug or its pharmaceutically acceptable salt and the photosensitizer, or (2) the anti-tumor drug or its pharmaceutically acceptable salt; the solvent in the second phase solution is an anti-solvent of the anti-tumor drug or its pharmaceutically acceptable salt, and the solute is (1) absent, or (2) a photosensitizer; when the solute in the first phase solution is an anti-tumor drug or its pharmaceutically acceptable salt and a photosensitizer, the solute in the second phase solution does not exist; when the solute in the first phase solution is an anti-tumor drug or its pharmaceutically acceptable salt, the solute in the second phase solution is a photosensitizer.

10. The method of claim 9, wherein the production method includes any of the following: a. preparation method for the continuous production of polymeric nanomicelles, and the method includes: (1) production system; (2) amphiphilic polymer; (3) anti-tumor drug; (4) one or more of the anti-tumor drugs or their pharmaceutically acceptable salts are dissolved in a first phase solvent, and the solvent for the first phase solution is a good solvent for the anti-tumor drugs or their pharmaceutically acceptable salts; (5) one or more of polymers are dissolved in a second phase solvent, and the solvent for the second phase solution is an anti-solvent for anti-tumor drugs or their pharmaceutically acceptable salts; (6) the first phase solution with the quantity of flow Q1 and the second phase solution with the quantity of flow Q2 are mixed in the combined phase; under the action of turbulent shear and ultrasound at the same time, the two-phase solutions mix rapidly to form a mixed solvent of the first phase and the second phase and produce a stably dispersed polymeric nanomicelles encapsulating anti-tumor drug with a certain particle size and distribution coefficient; b. preparation method for continuous production of polymeric nanomicelles, and the method includes: (1) production system; (2) amphiphilic polymer; (3) anti-tumor drug; (4) one or more of the anti-tumor drugs or their pharmaceutically acceptable salts and one or more of the amphiphilic polymers are dissolved in a first phase solvent, and the solvent for the first phase solution is a good solvent for the anti-tumor drugs or their pharmaceutically acceptable salts; (5) the solvent for the second phase solution is an anti-solvent for anti-tumor drugs or their pharmaceutically acceptable salts; (6) the first phase solution with the quantity of flow Q1 and the second phase solution with the quantity of flow Q2 are mixed in the combined phase; under the action of turbulent shear and ultrasound at the same time, the two-phase solutions mix rapidly to form a mixed solvent of the first phase and the second phase and produce a stably dispersed polymeric nanomicelles with a certain particle size and distribution coefficient; c. preparation method for continuous production of nanoliposomes, and the method includes: (1) production system; (3) the lipid component of the liposome is dissolved in the first phase, and the solvent used in the first phase solution is a good solvent for the lipid component; (4) the second phase solution is selected from water, aqueous buffer solution with a certain pH value and a certain osmotic pressure; (5) the first phase solution with the quantity of flow Q1 and the second phase solution with the quantity of flow Q2 are mixed in the combined phase; under the action of turbulent shear and ultrasound at the same time, the two-phase solutions mix rapidly to form a mixed solvent of the first phase and the second phase and produce a stably dispersed blank liposomes with a certain particle size and distribution coefficient; d. preparation method for continuous production of anti-tumor drug/photosensitizer nanoassemblies, and the method includes: (1) production system; (2) anti-tumor drugs and photosensitizers; (3) one or more of the anti-tumor drugs or their pharmaceutically acceptable salts are dissolved in a first phase solvent; (4) one or more of photosensitizers are dissolved in a second phase solvent, and the solvent for the second phase solution is an anti-solvent for anti-tumor drugs or their pharmaceutically acceptable salts; (5) the first phase solution with the quantity of flow Q1 and the second phase solution with the quantity of flow Q2 are mixed in the combined phase; under the action of turbulent shear and ultrasound at the same time, the two-phase solutions mix rapidly to form a mixed solvent of the first phase and the second phase and produce a stably dispersed anti-tumor drug/photosensitizer nanoassembly with a certain particle size and distribution coefficient; e. preparation method for continuous production of anti-tumor drug/photosensitizer nanoassemblies, and the method includes: (1) production system; (2) anti-tumor drugs and photosensitizers; (3) one or more of the anti-tumor drugs or their pharmaceutically acceptable salts and one or more of the photosensitizers are dissolved in a first phase solvent, and the solvent for the first phase solution is a good solvent for the anti-tumor drugs or their pharmaceutically acceptable salts; (4) the solvent for the second phase solution is an anti-solvent for anti-tumor drugs or their pharmaceutically acceptable salts; (5) the first phase solution with the quantity of flow Q1 and the second phase solution with the quantity of flow Q2 are mixed in the combined phase; under the action of turbulent shear and ultrasound at the same time, the two-phase solutions mix rapidly to form a mixed solvent of the first phase and the second phase and produce a stably dispersed anti-tumor drug/photosensitizer nanoassembly with a certain particle size and distribution coefficient; wherein the system includes (a) a first pipeline, (b) a second pipeline, (f) an ultrasonic device, (c) a combined pipeline and (e) a (fluid) outlet; wherein, the first pipeline and the second pipeline are connected to the combined pipeline, the first pipeline is coaxial with the combined pipeline and the second pipeline is perpendicular to the combined pipeline; the first pipeline outlet is positioned within the combined pipeline; the first phase solution enters the combined pipeline through the first pipeline outlet, the second phase solution enters the combined pipeline through the second pipeline outlet; the ultrasonic device acts on part or the whole of combined pipeline; the first phase solution and the second phase solution are mixed in the combined pipeline to form a combined phase; the combined phase flows out through the outlet of the combined pipeline; the amphiphilic polymer is selected from PEG-PLA, PEG-PCL, PEG-linker-PLA or PEG-linker-PCL, wherein, the linker is a linker selected from C1-C30 small molecule fragment; and the number average molecular weight of PEG is 400-20000 polyethylene glycol segments or mono-protected polyethylene glycol segments; the antitumor drug is selected from one or more of abemaciclib, abiraterone, abrocitinib, acalabrutinib, afatinib, aldesleukin, alectinib, alflutinib, almonertinib, altretamine, amcenestrant, aminoglutethimide, amsacrine, anastrozole, anlotinib, apalutamide, apatinib, arzoxifene, asciminib, asparaginase, avapritinib, avitinib, axitinib, azacitidine, baricitinib, belinostat, bendamustine, bexarotene, bicalutamide, bicyclol, binimetinib, bleomycin, boanmycin, bortezomib, bosutinib, brigatinib, buserelin, busulfan, cabazitaxel, cabozantinib, calaspargase, calicheamycin, capecitabine, capmatinib, carboplatin, carfilzomib, carmustine, carmofur, cedazuidine, ceritinib, cetrorelix, chidamide, chlorambucil, cisplatin, cladribine, clofarabine, cobimetinib, colchicine, copanlisib, crizotinib, cyclophosphamide, cytarabine, dabrafenib, dacarbazine, dacomitinib, dactinomycin, dalpiciclib, darolutamide, dasatinib, daunorubicin, decitabine, degarelix, delgociclib, denileukin, deruxtecan, docetaxel, donafenib, doxorubicin, duvelisib, enasidenib, encorafenib, ensartinib, entrectinib, enzalutamide, enzastaurin, elacestrant, epirubicin, erdafitinib, eribulin, erlotinib, estradiol, estramustine, etoposide, everolimus, exemestane, fasudil, fedatinib, filgotinib, floxuridine, fludarabine, flumatinib, fluorouracil, flutamide, fluzoparib, formestane, fostamatinib, fruquintinib, fulvestrant, gefitinib, gemcitabine, gilteritinib, giredestrant, glasdegib, goserelin, histrelin, hydroxyurea, ibrutinib, ibudilast, icaritin, icotinib, idarubicin, idelalisib, ifosfamide, imatinib, imiquimod, infigratinib, ingenol mebutate, interferon alfa-2b, irinotecan, ivosidenib, ixabepilone, ixazomib, lanreotide, lapatinib, larotrectinib, lenalidomide, lenvatinib, letrozole, leucovorin, leuprolide, lomustine, lonafarnib, lorlatinib, lurbinctedin, maytansine, mechlorethamine, medroxyprogesterone, megestrol, melphalan, melphlan flufenamide, mercaptopurine, methotrexate, methoxsalen, methylprednisolone, midostaurin, mitomycin, mitotane, mitoxantrone, mitozolomide, mobocertinib, monomethylauristatin E, monomethylauristatin F, nelarabine, nandrolone, neratinib, nearsudil, nilotinib, nilutamide, nintedanib, niraparib, octreotide, olaparib, olmutinib, omacetaxine, orelabrutinib, osimertinib, oxaliplatin, paclitaxel, pacritinib, palbociclib, pamidronate, pamiparib, panobinostat, pazopanib, peficitinib, pegaptanib, pegaspargase, peginteferon alfa-2b, pemigatinib, pemetrexed, pentetreotide, pentostatin, pexidartinib, phenoxybenzamine, pidotimod, plinabulin, plitidepsin, pomalidomide, ponatinib, porfimer, pralatrexate, pralsetinib, prednisolone, procarbazine, pyrotinib, quizartinib, radotinib, raloxifene, raltitrexed, regorafenib, ribociclib, rintatolimod, ripretinib, romidepsin, rucaparib, ruxolitinib, savolitinib, selinexor, selpercatinib, selumetinib, sonidegib, sorafenib, sotorasib, streptozocin, sunitinib, surufatinib, talazoparib, tamoxifen, tazemetostat, tegafur, temozolomide, temsirolimus, teniposide, tepotinib, teprenone, thalidomide, thioguanine, thiotepa, thyrotropin alfa, tipiracil, tipifarnib, tirabrutinib, tirbanibulin, tivozanib, trametinib, tofacitinib, topotecan, toremifene, trabectedin, tretinoin, trifluride, trilaciclib, triptorelin, tucatinib, upadacitinib, umbralisib, utidelone, uroacitide, valrubicin, vandetanib, vemurafenib, venetoclax, vinblastine, vincristine, vindesine, vinflunine, vinorelbine, vismodegib, vorinostat, zanubrutinib, zoledronic acid, amatoxins, anthacyclines, anthracenes, anthramycins, auristatins, bryostatins, camptothecins, carmaphycins, combretastatins, cyclosporines, cryptomycins, ecteinascidins, ellipticenes, esperamicins, mustines, neothramycins, ozogamicins, phenoxazines, podophyllotoxins, pyrrolobenzodiazepines, sibiromycins, thailanstatins, tomamycns, tubulysins, taxanes, vinca alkaloids, 7-epipaclitaxel, 2-acetylpaclitaxel, 10-deacetylpaclitaxel, 7-epi-10-deacetyltaxol, 7-xylosyltaxol, 10-deacetyl-7-glutarylpaclitaxel, 7-N,N-dimethylglycylpaclitaxel, 7-L-alanylacetaxel, larotaxel, camptothecin, 9-aminocamptothecin, 9-nitrocamptothecin, lurtotecan, gimatecan, belotecan, 10-hydroxycamptothecin, 10-hydroxy-7-ethyl-camptothecin (SN-38), exatecan, pirarubicin, aclacinomycin, sirolimus, tacrolimus, progesterone, estrogen, rapamycin, mithramycin, harringtonine or curcumin; the antitumor drug is preferably selected from one or more of camptothecin, 9-aminocamptothecin, 9-nitrocamptothecin, lurtotecan, gimatecan, belotecan, 10-hydroxycamptothecin, 10-hydroxy-7-ethyl-camptothecin (SN-38), exatecan, topotecan, deruxtecan, paclitaxel, docetaxel, cabazitaxel, 7-epipaclitaxel, 2-acetylpaclitaxel, 10-deacetylpaclitaxel, 7-epi-10-deacetyltaxol, 7-xylosyltaxol, 10-deacetyl-7-glutarylpaclitaxel, 7-N,N-dimethylglycylpaclitaxel, 7-L-alanylacetaxel, larotaxel, doxorubicin, epirubicin, daunorubicin, pirarubicin, aclacinomycin, etoposide, teniposide, vinblastine, vincristine, vinorelbine, vindesine, maytansine, curcumin, harringtonine, homoharringtonine, gemcitabine, capecitabine, fludarabine, cladribine, pemetrexed, bortezomib, carfilzomib, ixazomib, carmustine, fluorouracil, cytarabine, cyclosporine A, eribulin, trabectedin, gefitinib, erlotinib, lapatinib, afatinib, dacomitinib, vandetanib, neratinib, osimertinib, imatinib, sorafenib, sunitinib, lapatinib, dasatinib, olaparib, niraparib, rucaparib, fluzoparib, pamiparib, veliparib, talazoparib, apatinib, palbociclib, abemaciclib, ribociclib, and the photosensitizers include cyanine molecules, porphyrin molecules, porphyrin precursors, phthalocyanine molecules and chlorin molecules; wherein, the cyanine molecules are preferably selected from one or more of indocyanine green (IR780), new indocyanine green (IR820), indocyanine green and indocyanine green analogs; the porphyrin molecule is preferably selected from hematoporphyrin monomethyl ether; the porphyrin precursor is preferably selected from one of 5-aminolevulinic acid and 5-aminolevulinic acid esters; the phthalocyanine molecule is preferably selected from one or more of copper phthalocyanine, cobalt phthalocyanine, aluminum phthalocyanine, nickel phthalocyanine, calcium phthalocyanine, sodium phthalocyanine, magnesium phthalocyanine, zinc phthalocyanine, indium phthalocyanine, oxytitanium phthalocyanine, manganese phthalocyanine or phthalocyanine derivatives; the chlorin molecules are preferably selected from one or more of chlorins, talaporfin, verteporfin, temoporfin, rostaporfin, porfimer sodium, hemoporfin and HPPH.

11. The method of claim 9, wherein the production method fulfills one or more of the following: (1) the temperature of the first phase solution is 0-90 C., such as 25 C. or 60 C.; (2) the temperature of the second phase solution is 0-90 C., such as 25 C. or 60 C.; (3) the fluid Reynolds number Re of the combined phase is 700-9500 (e.g., 747, 2884, 3868, 5158, 5505, 5872, 6623, 7865 or 9176), preferably 3000-7000 (e.g., 3868, 5158 or 6623); (4) the flow velocity ratio FVR between the first phase solution and the combined phase is 0.4-6, such as 0.49, 0.64, 0.93, 1.46, 3.38, 3.4, 4.4 or 5.2; (5) the ultrasound is an ultrasonic water bath, and the ultrasonic power is 200 W; (6) the solvent used in the first phase solution and the second phase solution is water, aqueous buffer solution with a certain pH value, or an organic solvent miscible with water, and further, the organic solvent is one or more of methanol, ethanol, propanol, isopropanol, butanol, isobutanol, tert-butanol, DMF, DMAc, HMPA, N-methylpyrrolidone, DMSO, butyl sulfone, tetramethylene sulfone, THF, 2-methyltetrahydrofuran, acetonitrile, acetone, ethylene glycol, ethylene glycol methyl ether, ethylene glycol ethyl ether, dioxane, formic acid, acetic acid, hydroxypropionic acid, ethylamine, ethylenediamine, glycerol or pyridine; (7) the quantity of flow Q1 of the first phase solution through the first pipeline is selected from 10-100 ml/min, such as 10, 11, 14, 50, 60, 80 or 100; (8) the quantity of flow Q2 of the second phase solution through the second pipeline is selected from 100-1300 ml/min, such as 100, 193, 200, 210, 300, 936, 890 or 1248.

12. The method of claim 9, wherein the production method fulfills one or more of the following: (1) when the nano-formulation is polymeric nanomicelle, the concentration of the anti-tumor drug in the first phase solution ranges from 0.1-200 mg/ml, for example, it can be 0.1 mg/ml, 1 mg/ml, 5 mg/ml, 10 mg/ml, 20 mg/ml, 40 mg/ml, 60 mg/ml, 80 mg/ml, 100 mg/ml, 120 mg/ml, 140 mg/ml, 160 mg/ml, 180 mg/ml, 200 mg/ml, preferably 10-100 mg/ml, more preferably 10-20 mg/ml, such as 15 mg/ml; (2) when the nano-formulation is polymeric nanomicelle, the concentration of the polymer in the first phase solution or the second phase solution ranges from 0.1 to 200 mg/ml, for example, it can be 0.1 mg/ml, 1 mg/ml, 5 mg/ml, 10 mg/ml, 20 mg/ml, 40 mg/ml, 60 mg/ml, 80 mg/ml, 100 mg/ml, 120 mg/ml, 140 mg/ml, 160 mg/ml, 180 mg/ml, 200 mg/ml, preferably 10-100 mg/ml, such as 50 mg/ml; (3) when the nano-formulation is nanoliposome, the concentration of the lipid component in the first phase solution ranges from 0.1 to 200 mg/ml, for example, it can be 0.1 mg/ml, 1 mg/ml, 5 mg/ml, 10 mg/ml, 20 mg/ml, 40 mg/ml, 60 mg/ml, 80 mg/ml, 100 mg/ml, 120 mg/ml, 140 mg/ml, 160 mg/ml, 180 mg/ml, 200 mg/ml, preferably 10-100 mg/ml; (4) when the nano-formulation is anti-tumor drug/photosensitizer nanoassembly, the molar ratio of the anti-tumor drug or its pharmaceutically acceptable salt to the photosensitizer is (1-15): 1, such as 1:1, 2:1, 5:1, 6:1, 7:1, 8:1, 10:1 or 15:1, preferably 2:1; (5) when the nano-formulation is anti-tumor drug/photosensitizer nanoassembly, the concentration of the anti-tumor drug in the first phase solution ranges from 0.1 to 200 mg/ml, for example, it can be 0.1 mg/ml, 1 mg/ml, 5 mg/ml, 10 mg/ml, 20 mg/ml, 40 mg/ml, 60 mg/ml, 80 mg/ml, 100 mg/ml, 120 mg/ml, 140 mg/ml, 160 mg/ml, 180 mg/ml, 200 mg/ml, preferably 10-100 mg/ml, such as 40 mg/ml, 50 mg/ml or 100 mg/ml; (6) when the nano-formulation is anti-tumor drug/photosensitizer nanoassembly, the concentration of the photosensitizer in the first phase solution or the second phase solution ranges from 0.1 to 200 mg/ml, for example, it can be 0.1 mg/ml, 1 mg/ml, 5 mg/ml, 10 mg/ml, 20 mg/ml, 40 mg/ml, 60 mg/ml, 80 mg/ml, 100 mg/ml, 120 mg/ml, 140 mg/ml, 160 mg/ml, 180 mg/ml, 200 mg/ml, preferably 10-100 mg/ml, such as 40 mg/ml, 50 mg/ml or 150 mg/ml.

13. The method of claim 9, wherein the production method fulfills one or more of the following: (1) when the nano-formulation is polymeric nanomicelle, the solvent used in the first phase solution is nitrile solvent or alcohol solvent, such as acetonitrile or ethanol; (2) when the nano-formulation is polymeric nanomicelle, the solvent used in the second phase solution is water; (3) when the nano-formulation is liposome, the solvent used in the first phase solution is alcohol solvent, such as ethanol; (4) when the nano-formulation is liposome, the solvent used in the second phase solution is water or aqueous solution of ammonium sulfate, preferably water or an aqueous solution of 120 mM ammonium sulfate; (5) when the nano-formulation is polymer nanoparticle, the solvent used in the first phase solution is alcohol solvent or chlorinated alkane solvent, such as ethanol or methylene chloride; (6) when the nano-formulation is polymer nanoparticle, the solvent used for the second phase solution is water or water containing 0.5% PVA; (7) when the nano-formulation is anti-tumor drug/photosensitizer nanoassembly, the solvent used in the first phase solution is sulfoxide solvent, alcohol solvent, such as dimethyl sulfoxide or methanol; (8) when the nano-formulation is anti-tumor drug/photosensitizer nanoassembly, the solvent used in the second phase solution is water; (9) when the nano-formulation is lipid nanoparticle, the first phase solution is alcohol solvent, such as ethanol; (10) when the nano-formulation is lipid nanoparticle, the second phase solution is a citric acid buffer (pH 4.0).

14. The method of claim 9, wherein the particle size of nano-formulations is less than 1000 nm; preferably less than 500 nm; more preferably less than 200 nm; such as 20-200 nm.

15. The method of claim 9, wherein the polydispersity index of nano-formulations is less than 0.4.

16. A continuous production method for SN-38/indocyanine green nanoassemblies, and the method includes: (1) production system according to claim 1; (2) SN-38 and indocyanine green are dissolved in the first phase solution, wherein the solvent used in the first phase solution is a good solvent for SN-38 and indocyanine green; (3) the second phase solution is an anti-solvent for anti-tumor drugs or their pharmaceutically acceptable salts; (4) the first phase solution with the quantity of flow Q1 and the second phase solution with the quantity of flow Q2 are mixed in the combined phase; under the action of turbulent shear and ultrasound at the same time, the two-phase solutions mix rapidly to form a mixed solvent of the first phase and the second phase and produce a stably dispersed SN-38/indocyanine green nanoassembly with a certain particle size and distribution coefficient.

17. The method of claim 16, wherein the solvent used in the first phase solution and the second phase solution is water, aqueous buffer solution with a certain pH value or an organic solvent miscible with water, and further, the organic solvent is one or more of methanol, ethanol, propanol, isopropanol, butanol, isobutanol, tert-butanol, DMF, DMAc, HMPA, N-methylpyrrolidone, DMSO, butyl sulfone, tetramethylene sulfone, THF, 2-methyltetrahydrofuran, acetonitrile, acetone, ethylene glycol, ethylene glycol methyl ether, ethylene glycol ethyl ether, dioxane, formic acid, acetic acid, hydroxypropionic acid, ethylamine, ethylenediamine, glycerol or pyridine.

Description

DESCRIPTION OF FIGURES

[0128] FIG. 1: Schematic diagram of nano-formulation preparation device without static mixer

[0129] FIG. 2: Schematic diagram of nano-formulation preparation device with SK static mixer in the combined phase

[0130] FIG. 3: Example 4 particle size distribution of SN-38/ICG nanoparticles prepared under low turbulence conditions with/without ultrasonication

[0131] FIG. 4: Example 5 SN-38/ICG nanoparticle size distribution diagram, from which it can be concluded that when SN-38/ICG is prepared in small quantities (10-25 mL), the nanoparticles obtained by preparation device without ultrasonication show a distribution with single peak, and the average particle size is 984 nm.

[0132] FIG. 5: Example 6 SN-38/ICG nanoparticle size distribution diagram, from which it can be concluded that when SN-38/ICG is prepared in large quantities (1.0 L), the nanoparticles obtained by preparation device without ultrasonication show a distribution with double peaks, and the average particle size is 1116 nm.

[0133] FIG. 6: Example 7 SN-38/ICG nanoparticle size distribution diagram, from which it can be concluded that when SN-38/ICG is prepared in large quantities (1.0 L), the nanoparticles obtained under ultrasonication show a distribution with single peak, and the average particle size is 10910 nm.

[0134] FIG. 7: Example 20 and Example 21 particle size distribution diagram of HSPC/CHOL/DSPE-PEG blank liposomes, from which it can be concluded that when the HSPC/CHOL/DSPE-PEG blank liposomes are prepared without ultrasonication, the obtained blank liposomes show a distribution with multiple peaks.

[0135] FIG. 8: Example 22 and Example 23 HSPC/CHOL/DSPE-PEG blank liposome particle size distribution diagram, from which it can be concluded that when the HSPC/CHOL/DSPE-PEG blank liposomes are prepared under ultrasonication, the obtained blank liposomes show a distribution with single peak. The particle sizes are 131.72.9 nm and 115.31.6 nm, respectively.

[0136] FIG. 9: Example 24 PTX/HSPC/CHOL/DSPE-PEG liposome particle size distribution diagram, from which it can be concluded that when PTX/HSPC/CHOL/DSPE-PEG liposomes are prepared under ultrasonication, the obtained paclitaxel liposomes show a distribution with single peak, and the particle size is 81.11.7 nm.

[0137] FIG. 10: Example 27 PTX/PEG-PLA nanomicelle particle size distribution diagram, from which it can be concluded that when PTX/PEG-PLA nanomicelles are prepared under ultrasonication, the obtained nanomicelles show a distribution with single peak, and the particle size is 45.11.1 nm.

[0138] FIG. 11: Example 30 PEG-PLA nanoparticle size distribution diagram, from which it can be concluded that when PEG-PLA nanoparticles are prepared without ultrasonication, the obtained nanoparticles show a distribution with multiple peaks. The particle size is 69.57.3 nm, and the PI is 0.520.

[0139] FIG. 12: Example 31 PEG-PLA nanoparticle size distribution diagram, from which it can be concluded that when PEG-PLA nanoparticles are prepared under ultrasonication, the obtained nanoparticles show a distribution with single peak, the particle size is 25.00.1 nm, and the PI is 0.152.

[0140] FIG. 13: Example 32 PLGA nanoparticle size distribution diagram, from which it can be concluded that when PLGA nanoparticles are prepared under ultrasonication, the obtained nanoparticles show a distribution with single peak, the particle size is 218.52.1 nm, and the PI is 0.063.

[0141] FIG. 14: Example 33 PTX/PLGA nanoparticle size distribution diagram, from which it can be concluded that when PTX/PLGA nanoparticles are prepared under ultrasonication, the obtained nanoparticles show a distribution with single peak, the particle size is 225.91.2 nm, and the PI is 0.027.

[0142] FIG. 15: Example 34 PolyI lipid nanoparticle particle size distribution diagram, from which it can be concluded that when the PolyI lipid nanoparticle is prepared without ultrasonication, the obtained nanoparticles show a distribution with multiple peaks, the particle size is 89.6 nm, and the PI is 0.414.

[0143] FIG. 16: Example 35 PolyI lipid nanoparticle particle size distribution diagram, from which it can be concluded that when the PolyI lipid nanoparticle is prepared under ultrasonication, the obtained nanoparticles show a distribution with single peak, the particle size is 85.7 nm, and the PI is 0.214.

DETAILED DESCRIPTION OF THE EMBODIMENTS

[0144] The present invention is further described below by examples, but the present invention is not limited to the scope of the described examples. Experimental methods that do not indicate specific conditions in the following examples should be selected according to conventional methods and conditions, or according to product specifications.

[0145] The endpoints of ranges and any values disclosed herein are not limited to the precise range or value, but these ranges or values are to be understood to include values close to such ranges or values. For numerical ranges, the endpoint values of each range, the endpoint values of each range and individual point values, and the individual point values can be combined with each other to obtain one or more new numerical ranges. These numerical ranges shall be deemed to be specifically disclosed herein.

[0146] Unless otherwise specified, under ultrasonication in the present invention refers to the simultaneous action of ultrasound and turbulent mixing process of two phases.

[0147] The abbreviations used in the present invention are shown in the table below:

TABLE-US-00001 Abbreviation Full name D1(S) Diameter of a spray hole in the end of the first pipeline D2(IN) Inner diameter of the second pipeline D3(IN) Inner diameter of the combined pipeline Re Reynolds number Q1 The quantity of flow of the first pipe Q2 The quantity of flow of the second pipe t1 First phase solution temperature t2 Second phase solution temperature IR780 2-[2-[2-Chloro-3-[(1,3-dihydro-3,3-dimethyl-1-propyl- 2H-indol-2-ylidene)ethylidene]-1-cyclohexen-1- yl]ethenyl]-3,3-dimethyl-1-propylindolium iodide IR820 New indocyanine green ICG Indocyanine green SN-38 7-Ethyl-10-hydroxycamptothecin deruxtecan Deruxtecan DMF N,N-dimethylformamide DMAC N,N-dimethylacetamide DMSO Dimethyl sulfoxide THF Tetrahydrofuran HMPA Hexamethylphosphoramide siRNA Small interfering RNA Ce6 Chlorin e6 DOX Doxorubicin HCPT 10-Hydroxycamptothecin CPT11 Irinotecan PTX Paclitaxel UA Ursolic acid LA Lactobionic acid PLA Polylactic acid PCL Polycaprolactone PEG-PLA Methoxyl polyethylene glycol-polylactic acid copolymer PVA Polyvinyl alcohol PolyI Polyinosinic acid ALC-0315 Cationic lipid CAS#: 2036272-55-4 DSPE- 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine- PEG2000 polyethylene glycol 2000 HSPC Hydrogenated soy phosphatidylcholine PEG-Phe- Methoxyl polyethylene glycol-(CO-Phenylalanine-NH)- PLA polylactic acid copolymer FNP Flash nanoprecipitation CIJM Confined impinging jet mixer MIVM Multi-inlet vortex mixer FVR The flow velocity ratio

[0148] The turbulent mixing part in this application is a circular pipe with a certain diameter and length, and turbulent flow conditions are achieved through one or more of the following methods: [0149] 1) Increase flow velocity: [0150] Thorough mixing requires turbulence, Re>4000

Quantity of flow Q=d2/4*

Re=pd/=4Q/(d)>4000 [0151] When d=0.25 mm

Q>d=2.8 L/h [0152] When d=4 mm

Q>45 L/h [0153] When d=40 mm

Q>450 L/h [0154] Wherein, Re is the Reynolds number, Q is the quantity of flow, d is the pipeline diameter, is the fluid flow velocity in the pipe, u is the fluid viscosity, 20 C. water=10-3 Pa.Math.s

[0155] It should be pointed out that the preparation of certain composite nanoparticles of photosensitizers and anti-tumor drugs, nano-formulations with a certain particle size and particle size distribution can also be obtained with Re in the range of 500-4000. [0156] 2) Change the shape of the pipeline: [0157] By increasing the tortuosity of the pipeline, the direction of fluid flow is forcibly changed, which enhances the fluid mixing. [0158] 3) Add a static mixer to the pipeline:

[0159] The static mixer can include but is not limited to: SV type static mixer, SX type static mixer, SL type static mixer, SH type static mixers, SK type static mixers, etc. that can divide the fluid through turbulent mixing elements, change the flow direction of the fluid, enhance the convection of the fluid, and increase the mixing of the fluid.

[0160] The SV type static mixer unit is a cylinder assembled from certain regular wave plates.

[0161] The SX type static mixer unit consists of many X-shaped units composed of crossed horizontal bars according to certain rules.

[0162] The SL type static mixer unit is composed of crossed horizontal bars according to a certain pattern to form a single X-shaped unit.

[0163] The SK type static mixer unit is composed of single-channel left and right twisted spiral plates welded together.

[0164] The SH type static mixer unit is composed of double channels, with a fluid redistribution chamber between the units.

Example 1: Determination of Drug Concentration

[0165] Instrument: Agilent1260 HPLC [0166] Column: Waters XBridge C18 4.6*150 mm, 3.5 m [0167] Mobile phase: Use 10 mmol/L sodium dihydrogen phosphate solution (adjust to pH 4.0 with phosphoric acid) as phase A, use acetonitrile as phase B, and perform gradient elution according to the following table:

TABLE-US-00002 Time (min) A % B % 0 80 20 10 20 80 11 80 20 16 80 20 [0168] Chromatographic parameters: flow velocity: 1 ml/min; column temperature: 35 C.; detection wavelength: 264 nm; injection volume: 10 l [0169] Calculation method: Peak area external standard method

Example 2: Determination of Nanoparticle Size

[0170] Dynamic light scattering method: The concentration of nanoparticles is 10-100 g/ml, and the particle size and distribution of nanoparticles are measured with a nanoparticle sizer (laser light source 633 nm). Each sample is measured three times, and the average and variance of the nanoparticle size are calculated.

Example 3: Determination of Drug Encapsulation Efficiency

[0171] Take 1 ml of nanoparticle solution, filter with a 0.22 m nylon needle filter, and measure the hydrophobic drug concentration by HPLC.

[00001]$\mathrm{Hydrophobic}\mathrm{drug}\mathrm{encapsulation}\mathrm{efficiency}\%=\frac{\mathrm{Hydrophobic}\mathrm{drug}\mathrm{concentration}\mathrm{after}\mathrm{filtration}}{\mathrm{Hydrophobic}\mathrm{drug}\mathrm{concentration}\mathrm{before}\mathrm{filtration}}100\%$

Example 4: Preparation of SN-38/ICG Nanoparticles (SK Type Static Mixer, First Phase 11 ml/min, Second Phase 193 ml/min, 20 ml Produced)

[0172] First phase solution: ICG and SN-38 were dissolved in DMSO, SN-38 content: 3.394 wt. %, ICG content: 3.397 wt. %, SN-38 to ICG molar ratio was 2:1, filtration with 0.22 m nylon filter membrane. [0173] Second phase solution: water [0174] Spray hole diameter at the end of first pipeline D1(S)=0.6 mm; [0175] Inner diameter of the second pipeline D2(IN)=5.4 mm; [0176] Inner diameter of the combined pipeline D3(IN)=5.4 mm; [0177] Outer diameter at the end of first pipeline D1(O)=2 mm; [0178] Outer diameter of the second pipeline D2(O)=6 mm; [0179] Outer diameter of the combined pipeline D3(O)=6 mm; [0180] Combined phase length=90 mm; [0181] First phase solution temperature t.sub.1=25 C.; [0182] Second phase solution temperature t.sub.2=25 C.;

TABLE-US-00003 First phase Second phase ml/min ml/min 11 193

[0183] Calculated based on the fluid in the circular pipeline, the combined phase Re=747, with SK type static mixer, static mixer size: 5.3 mm*85 mm, with a total of 16 repeating spiral plates. [0184] The first phase outlet flow velocity is: 0.648 m/s [0185] The combined phase flow velocity is: 0.148 m/s [0186] FVR=4.4 [0187] Production quantity: 20 ml

TABLE-US-00004 Average Filtration Ultra D10 D50 D90 diameter encapsulation sound (nm) (nm) (nm) (nm) PDI efficiency (SN-38) (1) Y* 96 4 115 7 142 13 98 8 0.31 0.19 94.8% (2) N 88 16 231 85 413 34 167 7 0.45 0.05 53.6% *Under the simultaneous action of ultrasound and turbulent mixing, the two phases were combined in a 200 W ultrasonic bath.

[0188] By comparing (1) and (2) above, the encapsulation efficiency of SN-38 increased from 53.5% to 94.8%, the particle size distribution changed from multiple peaks to single peak (FIG. 3), and the average particle size decreased significantly.

Example 1: Preparation of SN-38/ICG Nanoparticles (First Phase 60 ml/min, Second Phase 936 ml/min, without Ultrasonication, 20 ml Produced)

[0189] First phase solution: ICG and SN-38 were dissolved in DMSO, SN-38 content: 3.394 wt. %, ICG content: 3.397 wt. %, SN-38 to ICG molar ratio was 2:1, filtration with 0.22 m nylon filter membrane. [0190] Second phase solution: water [0191] Spray hole diameter at the end of first pipeline D1(S)=0.6 mm; [0192] Inner diameter of the second pipeline D2(IN)=5.4 mm; [0193] Inner diameter of the combined pipeline D3(IN)=5.4 mm; [0194] Outer diameter at the end of first pipeline D1(O)=2 mm; [0195] Outer diameter of the second pipeline D2(O)=6 mm; [0196] Outer diameter of the combined pipeline D3(O)=6 mm; [0197] Combined phase length=90 mm; [0198] First phase solution temperature t.sub.1=25 C.; [0199] Second phase solution temperature t.sub.2=25 C.;

TABLE-US-00005 First phase Second phase ml/min ml/min 60 936

[0200] Calculated based on the fluid in the circular pipeline, the combined phase Re=3868, with no static mixer. [0201] The first phase outlet flow velocity is: 3.54 m/s [0202] The second phase flow velocity is: 0.68 m/s [0203] FVR=5.2 [0204] Production quantity: 20 ml

TABLE-US-00006 Average Encapsulation D10 D50 D90 diameter efficiency nm nm nm nm D90/D10 (SN-38) 79 7 96 8 124 13 98 4 1.57 98.4%

Example 2: Preparation of SN-38/ICG Nanoparticles (First Phase 60 ml/min, Second Phase 936 ml/min, without Ultrasonication, 1.0 L Produced)

[0205] First phase solution: ICG and SN-38 were dissolved in DMSO, SN-38 content: 3.394 wt. %, ICG content: 3.397 wt. %, SN-38 to ICG molar ratio was 2:1, filtration with 0.22 m nylon filter membrane. [0206] Second phase solution: water [0207] Spray hole diameter at the end of first pipeline D.sub.1(S)=0.6 mm; [0208] Inner diameter of the second pipeline D.sub.2(IN)=5.4 mm; [0209] Inner diameter of the combined pipeline D.sub.3(IN)=5.4 mm; [0210] Outer diameter at the end of first pipeline D.sub.1(O)=2 mm; [0211] Outer diameter of the second pipeline D.sub.2(O)=6 mm; [0212] Outer diameter of the combined pipeline D.sub.3(O)=6 mm; [0213] Combined phase length=360 mm; [0214] First phase solution temperature t.sub.1=25 C.; [0215] Second phase solution temperature t.sub.2=25 C.;

TABLE-US-00007 First phase Second phase ml/min ml/min 60 936

[0216] Calculated based on the fluid in the circular pipeline, the combined phase Re=3868, with no static mixer. [0217] The first phase outlet flow velocity is: 3.54 m/s [0218] The second phase flow velocity is: 0.68 m/s [0219] FVR=5.2 [0220] Production quantity: 1.0 L

TABLE-US-00008 Average Encapsulation D10 D50 D90 diameter efficiency nm nm nm nm D90/D10 (SN-38) 82 3 115 6 196 3 111 6 2.39 92.4%

[0221] Comparing examples 5 and 6, for the scale-up preparation of nanoparticles (from 20 mL to 1000 mL), the encapsulation efficiency decreases significantly, the ratio of D90 to D10 increases significantly, and the particle size shows a distribution with multiple peaks without ultrasonication (FIG. 5).

Example 3: Preparation of SN-38/ICG Nanoparticles (First Phase 60 ml/min, Second Phase 936 ml/min, Under Ultrasonication, 1.0 L Produced)

[0222] First phase solution: ICG and SN-38 were dissolved in DMSO, SN-38 content: 3.394 wt. %, ICG content: 3.397 wt. %, SN-38 to ICG molar ratio was 2:1, filtration with 0.22 m nylon filter membrane. [0223] Second phase solution: water [0224] Spray hole diameter at the end of first pipeline D.sub.1(S)=0.6 mm; [0225] Inner diameter of the second pipeline D.sub.2(IN)=5.4 mm; [0226] Inner diameter of the combined pipeline D.sub.3(IN)=5.4 mm; [0227] Outer diameter at the end of first pipeline D.sub.1(O)=2 mm; [0228] Outer diameter of the second pipeline D.sub.2(O)=6 mm; [0229] Outer diameter of the combined pipeline D.sub.3(O)=6 mm; [0230] Combined phase length=360 mm; [0231] First phase solution temperature t.sub.1=25 C.; [0232] Second phase solution temperature t.sub.2=25 C.; [0233] Two phases combine in a 200 W ultrasonic bath

TABLE-US-00009 First phase Second phase ml/min ml/min 60 936

[0234] Calculated based on the fluid in the circular pipeline, the combined phase Re=3868, with no static mixer. [0235] The first phase outlet flow velocity is: 3.54 m/s [0236] The second phase flow velocity is: 0.68 m/s [0237] FVR=5.2 [0238] Production quantity: 1.0 L

TABLE-US-00010 Average Encapsulation D10 D50 D90 diameter efficiency nm nm nm nm D90/D10 (SN-38) 89 10 100 12 145 16 109 10 1.63 97.5%

[0239] Comparing examples 7 and 6, for the scale-up preparation of nanoparticles under ultrasonication, the encapsulation efficiency is significantly increased (97.5% vs 92.4%), the ratio of D90 to D10 is reduced (1.63 vs 2.39), and the particle size shows a distribution with single peak (FIG. 6). Under ultrasonication, the scale-up preparation of nanoparticles is similar to the experimental results of the small amount preparation conditions (Example 5).

Example 4: Preparation of SN-38/ICG Nanoparticles (SK Type Static Mixer, First Phase 80 ml/min, Second Phase 1248 ml/min, 20 ml Produced)

[0240] First phase solution: ICG and SN-38 were dissolved in DMSO, SN-38 content: 3.394 wt. %, ICG content: 3.397 wt. %, SN-38 to ICG molar ratio was 2:1, filtration with 0.22 m nylon filter membrane. [0241] Second phase solution: water [0242] Spray hole diameter at the end of first pipeline D.sub.1(S)=0.6 mm; [0243] Inner diameter of the second pipeline D.sub.2(IN)=5.4 mm; [0244] Inner diameter of the combined pipeline D.sub.3(IN)=5.4 mm; [0245] Outer diameter at the end of first pipeline D.sub.1(O)=2 mm; [0246] Outer diameter of the second pipeline D.sub.2(O)=6 mm; [0247] Outer diameter of the combined pipeline D.sub.3(O)=6 mm; [0248] Combined phase length=90 mm; [0249] First phase solution temperature t.sub.1=25 C.; [0250] Second phase solution temperature t.sub.2=25 C.;

TABLE-US-00011 First phase Second phase ml/min ml/min 80 1248

[0251] Calculated based on the fluid in the circular pipeline, the combined phase Re=5158, with SK type static mixer, static mixer size: 5.3 mm*85 mm, with a total of 16 repeating spiral plates. [0252] The first phase outlet flow velocity is: 4.72 m/s [0253] The second phase flow velocity is: 0.91 m/s [0254] FVR=5.2 [0255] Production quantity: 20 ml

TABLE-US-00012 Average Encapsulation D10 D50 D90 diameter efficiency nm nm nm nm D90/D10 (SN-38) 83 17 101 23 126 35 109 5 1.52 98.8%

Example 5: Preparation of SN-38/ICG Nanoparticles (SK Type Static Mixer, First Phase 80 ml/min, Second Phase 1248 ml/min, without Ultrasonication, 425 ml Produced)

[0256] First phase solution: ICG and SN-38 were dissolved in DMSO, SN-38 content: 3.394 wt. %, ICG content: 3.397 wt. %, SN-38 to ICG molar ratio was 2:1, filtration with 0.22 m nylon filter membrane. [0257] Second phase solution: water [0258] Spray hole diameter at the end of first pipeline D.sub.1(S)=0.6 mm; [0259] Inner diameter of the second pipeline D.sub.2(IN)=5.4 mm; [0260] Inner diameter of the combined pipeline D.sub.3(IN)=5.4 mm; [0261] Outer diameter at the end of first pipeline D.sub.1(O)=2 mm; [0262] Outer diameter of the second pipeline D.sub.2(O)=6 mm; [0263] Outer diameter of the combined pipeline D.sub.3(O)=6 mm; [0264] Combined phase length=90 mm; [0265] First phase solution temperature t.sub.1=25 C.; [0266] Second phase solution temperature t.sub.2=25 C.;

TABLE-US-00013 First phase Second phase ml/min ml/min 80 1248

[0267] Calculated based on the fluid in the circular pipeline, the combined phase Re=5158, with SK type static mixer, static mixer size: 5.3 mm*85 mm, with a total of 16 repeating spiral plates. [0268] The first phase outlet flow velocity is: 4.72 m/s [0269] The second phase flow velocity is: 0.91 m/s [0270] FVR=5.2 [0271] Production quantity: 425 ml

TABLE-US-00014 Average Encapsulation D10 D50 D90 diameter efficiency nm nm nm nm D90/D10 (SN-38) 93 3 121 1 180 10 126 4 1.94 92.2%

[0272] Comparing Examples 8 and 9, for the scale-up preparation of nanoparticles without ultrasonication (from 20 mL to 425 mL), the encapsulation efficiency decreases significantly and the ratio of D90 to D10 increases.

Example 6: Preparation of SN-38/ICG Nanoparticles (SK Type Static Mixer, First Phase 80 ml/min, Second Phase 1248 ml/min, Under Ultrasonication, 425 ml Produced)

[0273] First phase solution: ICG and SN-38 were dissolved in DMSO, SN-38 content: 3.394 wt. %, ICG content: 3.397 wt. %, SN-38 to ICG molar ratio was 2:1, filtration with 0.22 m nylon filter membrane. [0274] Second phase solution: water [0275] Spray hole diameter at the end of first pipeline D.sub.1(S)=0.6 mm; [0276] Inner diameter of the second pipeline D.sub.2(IN)=5.4 mm; [0277] Inner diameter of the combined pipeline D.sub.3(IN)=5.4 mm; [0278] Outer diameter at the end of first pipeline D.sub.1(O)=2 mm; [0279] Outer diameter of the second pipeline D.sub.2(O)=6 mm; [0280] Outer diameter of the combined pipeline D.sub.3(O)=6 mm; [0281] Combined phase length=90 mm; [0282] First phase solution temperature t.sub.1=25 C.; [0283] Second phase solution temperature t.sub.2=25 C.; [0284] Two phases combine in a 200 W ultrasonic bath

TABLE-US-00015 First phase Second phase ml/min ml/min 80 1248

[0285] Calculated based on the fluid in the circular pipeline, the combined phase Re=5158, with SK type static mixer, static mixer size: 5.3 mm*85 mm, with a total of 16 repeating spiral plates. [0286] The first phase outlet flow velocity is: 4.72 m/s [0287] The second phase flow velocity is: 0.91 m/s [0288] FVR=5.2 [0289] Production quantity: 425 ml

TABLE-US-00016 Average Encapsulation D10 D50 D90 diameter efficiency nm nm nm nm D90/D10 (SN-38) 96 1 116 4 146 10 113 4 1.52 97.0%

[0290] Comparing examples 10 and 9, for the scale-up preparation of nanoparticles under ultrasonication, the encapsulation efficiency is significantly increased (97.0% vs 92.2%), the ratio of D90 to D10 is reduced (1.52 vs 1.94), and the particle size shows a distribution with single peak. Under ultrasonication, the scale-up preparation of nanoparticles is similar to the experimental results of the small amount preparation conditions (Example 8).

Example 7: Preparation of PTX/ICG Nanoparticles (First Phase 60 ml/min, Second Phase 890 ml/min, without Ultrasonication, 20 mL Produced)

[0291] First phase solution: PTX and ICG were co-dissolved in methanol, PTX concentration; 100 mg/ml, ICG concentration: 50 mg/ml, filtration with 0.22 m nylon filter membrane. [0292] Second phase solution: water [0293] Spray hole diameter at the end of first pipeline D.sub.1(S)=0.4 mm; [0294] Inner diameter of the second pipeline D.sub.2(IN)=3.0 mm; [0295] Inner diameter of the combined pipeline D.sub.3(IN)=3.0 mm; [0296] Outer diameter at the end of first pipeline D.sub.1(O)=1.0 mm; [0297] Combined phase length=90 mm; [0298] First phase solution temperature t.sub.1=25 C.; [0299] Second phase solution temperature t.sub.2=25 C.;

TABLE-US-00017 First phase Second phase ml/min ml/min 60 890

[0300] Calculated based on the fluid in the circular pipeline, the combined phase Re=6623. [0301] The first phase outlet flow velocity is: 7.58 m/s [0302] The second phase flow velocity is: 2.24 m/s [0303] FVR=3.38 [0304] Production quantity: 20 ml

TABLE-US-00018 Average Encapsulation D10 D50 D90 diameter efficiency nm nm nm nm D90/D10 (PTX) 68 3 79 4 90 9 75 3 1.32 98.2%

Example 8: Preparation of PTX/ICG Nanoparticles (First Phase 60 ml/min, Second Phase 890 ml/min, without Ultrasonication, 400 mL Produced)

[0305] First phase solution: PTX and ICG were co-dissolved in methanol, PTX concentration: 100 mg/ml, ICG concentration: 50 mg/ml, filtration with 0.22 m nylon filter membrane. [0306] Second phase solution: water [0307] Spray hole diameter at the end of first pipeline D.sub.1(S)=0.4 mm; [0308] Inner diameter of the second pipeline D.sub.2(IN)=3.0 mm; [0309] Inner diameter of the combined pipeline D.sub.3(IN)=3.0 mm; [0310] Outer diameter at the end of first pipeline D.sub.1(O)=1.0 mm; [0311] Combined phase length=90 mm; [0312] First phase solution temperature t.sub.1=25 C.; [0313] Second phase solution temperature t.sub.2=25 C.;

TABLE-US-00019 First phase Second phase ml/min ml/min 60 890

[0314] Calculated based on the fluid in the circular pipeline, the combined phase Re=6623. [0315] The first phase outlet flow velocity is: 7.58 m/s [0316] The second phase flow velocity is: 2.24 m/s [0317] FVR=3.38 [0318] Production quantity: 400 ml

TABLE-US-00020 Average Encapsulation D10 D50 D90 diameter efficiency nm nm nm nm D90/D10 (PTX) 64 7 82 5 102 13 81 5 1.59 93.4%

[0319] Comparing Examples 11 and 12, for the scale-up preparation of nanoparticles without ultrasonication (from 20 mL to 400 mL), the encapsulation efficiency decreases significantly and the ratio of D90 to D10 increases.

Example 9: Preparation of PTX/ICG Nanoparticles (First Phase 60 ml/min, Second Phase 890 ml/min, Under Ultrasonication, 400 mL Produced)

[0320] First phase solution: PTX and ICG were co-dissolved in methanol, PTX concentration: 100 mg/ml, ICG concentration: 50 mg/ml, filtration with 0.22 m nylon filter membrane. [0321] Second phase solution: water [0322] Spray hole diameter at the end of first pipeline D.sub.1(S)=0.4 mm; [0323] Inner diameter of the second pipeline D.sub.2(IN)=3.0 mm; [0324] Inner diameter of the combined pipeline D.sub.3(IN)=3.0 mm; [0325] Outer diameter at the end of first pipeline D.sub.1(O)=1.0 mm; [0326] Combined phase length=90 mm; [0327] First phase solution temperature t.sub.1=25 C.; [0328] Second phase solution temperature t.sub.2=25 C.; [0329] Two phases combine in a 200 W ultrasonic bath

TABLE-US-00021 First phase Second phase ml/min ml/min 60 890

[0330] Calculated based on the fluid in the circular pipeline, the combined phase Re-6623. [0331] The first phase outlet flow velocity is: 7.58 m/s [0332] The second phase flow velocity is: 2.24 m/s [0333] FVR=3.38 [0334] Production quantity: 400 ml

TABLE-US-00022 Average Encapsulation D10 D50 D90 diameter efficiency nm nm nm nm D90/D10 (PTX) 70 3 74 2 89 10 72 2 1.27 98.7%

[0335] Comparing examples 13 and 12, for the scale-up preparation of nanoparticles under ultrasonication, the encapsulation efficiency is significantly increased (98.7% vs 93.4%), the ratio of D90 to D10 is reduced (1.27 vs 1.59), and the particle size shows a distribution with single peak. Under ultrasonication, the scale-up preparation of nanoparticles is similar to the experimental results of the small amount preparation conditions (Example 11).

Example 10: Preparation of Curcumin/CPT11 Nanoparticles (First Phase 60 ml/min, Second Phase 890 ml/min, without Ultrasonication, 20 mL Produced)

[0336] First phase solution: curcumin and CPT11 were co-dissolved in DMSO, curcumin concentration: 50 mg/ml, CPT11 concentration: 150 mg/ml, filtration with 0.22 m nylon filter membrane. [0337] Second phase solution: water [0338] Spray hole diameter at the end of first pipeline D.sub.1(S)=0.4 mm; [0339] Inner diameter of the second pipeline D.sub.2(IN)=3.0 mm; [0340] Inner diameter of the combined pipeline D.sub.3(IN)=3.0 mm; [0341] Outer diameter at the end of first pipeline D.sub.1(O)=1.0 mm; [0342] Combined phase length=90 mm; [0343] First phase solution temperature t.sub.1=25 C.; [0344] Second phase solution temperature t.sub.2=25 C.;

TABLE-US-00023 First phase Second phase ml/min ml/min 60 890

[0345] Calculated based on the fluid in the circular pipeline, the combined phase Re-6623. [0346] The first phase outlet flow velocity is: 7.58 m/s [0347] The second phase flow velocity is: 2.24 m/s [0348] FVR=3.38 [0349] Production quantity: 20 ml

TABLE-US-00024 Average Encapsulation D10 D50 D90 diameter efficiency nm nm nm nm D90/D10 (curcumin) 80 3 93 2 113 1 96 2 1.41 97.4%

Example 11: Preparation of Curcumin/CPT11 Nanoparticles (First Phase 60 ml/min, Second Phase 890 ml/min, without Ultrasonication, 400 mL Produced)

[0350] First phase solution: curcumin and CPT11 were co-dissolved in DMSO, curcumin concentration: 50 mg/ml, CPT11 concentration: 150 mg/ml, filtration with 0.22 m nylon filter membrane. [0351] Second phase solution: water [0352] Spray hole diameter at the end of first pipeline D.sub.1(S)=0.4 mm; [0353] Inner diameter of the second pipeline D.sub.2(IN)=3.0 mm; [0354] Inner diameter of the combined pipeline D.sub.3(IN)=3.0 mm; [0355] Outer diameter at the end of first pipeline D.sub.1(O)=1.0 mm; [0356] Combined phase length=90 mm; [0357] First phase solution temperature t.sub.1=25 C.; [0358] Second phase solution temperature t.sub.2=25 C.;

TABLE-US-00025 First phase Second phase ml/min ml/min 60 890

[0359] Calculated based on the fluid in the circular pipeline, the combined phase Re-6623. [0360] The first phase outlet flow velocity is: 7.58 m/s [0361] The second phase flow velocity is: 2.24 m/s [0362] FVR=3.38 [0363] Production quantity: 400 ml

TABLE-US-00026 Average Encapsulation D10 D50 D90 diameter efficiency nm nm nm nm D90/D10 (curcumin) 83 5 96 7 149 15 103 13 1.80 93.6%

[0364] Comparing Examples 15 and 14, for the scale-up preparation of nanoparticles without ultrasonication (from 20 mL to 400 mL), the encapsulation efficiency decreases significantly and the ratio of D90 to D10 increases.

Example 12: Preparation of Curcumin/CPT11 Nanoparticles (First Phase 60 ml/min, Second Phase 890 ml/min, Under Ultrasonication, 400 mL Produced)

[0365] First phase solution: curcumin and CPT11 were co-dissolved in DMSO, curcumin concentration: 50 mg/ml, CPT11 concentration: 150 mg/ml, filtration with 0.22 m nylon filter membrane. [0366] Second phase solution: water [0367] Spray hole diameter at the end of first pipeline D.sub.1(S)=0.4 mm; [0368] Inner diameter of the second pipeline D.sub.2(IN)=3.0 mm; [0369] Inner diameter of the combined pipeline D.sub.3(IN)=3.0 mm; [0370] Outer diameter at the end of first pipeline D.sub.1(O)=1.0 mm; [0371] Combined phase length=90 mm; [0372] First phase solution temperature t.sub.1=25 C.; [0373] Second phase solution temperature t.sub.2=25 C.; [0374] Two phases combine in a 200 W ultrasonic bath

TABLE-US-00027 First phase Second phase ml/min ml/min 60 890

[0375] Calculated based on the fluid in the circular pipeline, the combined phase Re=6623. [0376] The first phase outlet flow velocity is: 7.58 m/s [0377] The second phase flow velocity is: 2.24 m/s [0378] FVR=3.38 [0379] Production quantity: 400 ml

TABLE-US-00028 Average Encapsulation D10 D50 D90 diameter efficiency nm nm nm nm D90/D10 (curcumin) 75 2 87 3 105 4 91 4 1.40 98.2%

[0380] Comparing Examples 16 and 15, for the scale-up preparation of nanoparticles under ultrasonication, the encapsulation efficiency is significantly increased (98.2% vs 93.6%), the ratio of D90 to D10 is reduced (1.40 vs 1.80), and the particle size shows a distribution with single peak. Under ultrasonication, the scale-up preparation of nanoparticles is similar to the experimental results of the small amount preparation conditions (Example 14).

Example 13: Preparation of SN-38/CPT11 Nanoparticles (First Phase 60 ml/min, Second Phase 890 ml/min, without Ultrasonication, 20 mL Produced)

[0381] First phase solution: SN-38 and CPT11 were co-dissolved in DMSO, SN-38 concentration: 40 mg/ml, CPT11 concentration: 40 mg/ml, filtration with 0.22 m nylon filter membrane. [0382] Second phase solution: water [0383] Spray hole diameter at the end of first pipeline D.sub.1(S)=0.4 mm; [0384] Inner diameter of the second pipeline D.sub.2(IN)=3.0 mm; [0385] Inner diameter of the combined pipeline D.sub.3(IN)=3.0 mm; [0386] Outer diameter at the end of first pipeline D.sub.1(O)=1.0 mm; [0387] Combined phase length=90 mm; [0388] First phase solution temperature t.sub.1=25 C.; [0389] Second phase solution temperature t.sub.2=25 C.;

TABLE-US-00029 First phase Second phase ml/min ml/min 60 890

[0390] Calculated based on the fluid in the circular pipeline, the combined phase Re-6623. [0391] The first phase outlet flow velocity is: 7.58 m/s [0392] The second phase flow velocity is: 2.24 m/s [0393] FVR=3.38 [0394] Production quantity: 20 ml

TABLE-US-00030 Average Encapsulation D10 D50 D90 diameter efficiency nm nm nm nm D90/D10 (SN-38) 89 6 95 3 109 4 93 2 1.22 97.8%

Example 14: Preparation of SN-38/CPT11 Nanoparticles (First Phase 60 ml/min, Second Phase 890 ml/min, without Ultrasonication, 400 mL Produced)

[0395] First phase solution: SN-38 and CPT11 were co-dissolved in DMSO, SN-38 concentration: 40 mg/ml, CPT11 concentration: 40 mg/ml, filtration with 0.22 m nylon filter membrane. [0396] Second phase solution: water [0397] Spray hole diameter at the end of first pipeline D.sub.1(S)=0.4 mm; [0398] Inner diameter of the second pipeline D.sub.2(IN)=3.0 mm; [0399] Inner diameter of the combined pipeline D.sub.3(IN)=3.0 mm; [0400] Outer diameter at the end of first pipeline D.sub.1(O)=1.0 mm; [0401] Combined phase length=90 mm; [0402] First phase solution temperature t.sub.1=25 C.; [0403] Second phase solution temperature t.sub.2=25 C.;

TABLE-US-00031 First phase Second phase ml/min ml/min 60 890

[0404] Calculated based on the fluid in the circular pipeline, the combined phase Re-6623. [0405] The first phase outlet flow velocity is: 7.58 m/s [0406] The second phase flow velocity is: 2.24 m/s [0407] FVR=3.38 [0408] Production quantity: 400 ml

TABLE-US-00032 Average Encapsulation D10 D50 D90 diameter efficiency nm nm nm nm D90/D10 (SN-38) 76 5 108 7 154 16 97 5 2.02 90.2%

[0409] Comparing Examples 17 and 18, for the scale-up preparation of nanoparticles without ultrasonication (from 20 mL to 400 mL), the encapsulation efficiency decreases significantly and the ratio of D90 to D10 increases.

Example 15: Preparation of SN-38/CPT11 Nanoparticles (First Phase 60 ml/min, Second Phase 890 ml/min, Under Ultrasonication, 400 mL Produced)

[0410] First phase solution: SN-38 and CPT11 were co-dissolved in DMSO, SN-38 concentration: 40 mg/ml, CPT11 concentration: 40 mg/ml, filtration with 0.22 m nylon filter membrane. [0411] Second phase solution: water [0412] Spray hole diameter at the end of first pipeline D.sub.1(S)=0.4 mm; [0413] Inner diameter of the second pipeline D.sub.2(IN)=3.0 mm; [0414] Inner diameter of the combined pipeline D.sub.3(IN)=3.0 mm; [0415] Outer diameter at the end of first pipeline D.sub.1(O)=1.0 mm; [0416] Combined phase length=90 mm; [0417] First phase solution temperature t.sub.1=25 C.; [0418] Second phase solution temperature t.sub.2=25 C.; [0419] Two phases combine in a 200 W ultrasonic bath

TABLE-US-00033 First phase Second phase ml/min ml/min 60 890

[0420] Calculated based on the fluid in the circular pipeline, the combined phase Re=6623. [0421] The first phase outlet flow velocity is: 7.58 m/s [0422] The second phase flow velocity is: 2.24 m/s [0423] FVR=3.38 [0424] Production quantity: 400 ml

TABLE-US-00034 Average Encapsulation D10 D50 D90 diameter efficiency nm nm nm nm D90/D10 (SN-38) 92 3 97 4 107 2 94 3 1.16 98.1%

[0425] Comparing Examples 19 and 18, for the scale-up preparation of nanoparticles under ultrasonication, the encapsulation efficiency is significantly increased (98.1% vs 90.2%), the ratio of D90 to D10 is reduced (1.16 vs 2.02), and the particle size shows a distribution with single peak. Under ultrasonication, the scale-up preparation of nanoparticles is similar to the experimental results of the small amount preparation conditions (Example 17).

Example 16: Preparation of HSPC/CHOL/DSPE-PEG Blank Liposome (First Phase 10 ml/min, Second Phase 100 ml/min, without Ultrasonication, 50 mL Produced)

[0426] First phase solution: HSPC, CHOL, DSPE-PEG2k were co-dissolved in ethanol and filtered with 0.22 m nylon filter membrane. HSPC: CHOL: DSPE-PEG2k=56:38:5 (molar ratio), HSPC concentration: 10 mg/ml. [0427] Second phase solution: 120 mM ammonium sulfate in water. [0428] Spray hole diameter at the end of first pipeline D.sub.1(S)=0.25 mm; [0429] Inner diameter of the second pipeline D.sub.2(IN)=0.8 mm; [0430] Inner diameter of the combined pipeline D.sub.3(IN)=0.8 mm; [0431] Outer diameter at the end of first pipeline D.sub.1(O)=0.35 mm; [0432] Combined phase length=360 mm; [0433] First phase solution temperature t.sub.1=25 C.; [0434] Second phase solution temperature t.sub.2=25 C.;

TABLE-US-00035 First phase Second phase ml/min ml/min 10 100

[0435] Calculated based on the fluid in the circular pipeline, the combined phase Re=2884.

[0436] The first phase outlet flow velocity is: 3.4 m/s

[0437] The second phase flow velocity is: 3.65 m/s

[0438] FVR=0.93

[0439] Production quantity: 50 ml

TABLE-US-00036 Average D10 D50 D90 diameter Encapsulation nm nm nm nm D90/D10 efficiency 53 57 162 32 208 63 3.92

[0440] The particle size of blank liposomes prepared without ultrasonication showed a distribution with multiple peaks (FIG. 7), and there were large particle size distributions and variances in blank liposomes.

Example 17: Preparation of HSPC/CHOL/DSPE-PEG Blank Liposome (First Phase 10 ml/min, Second Phase 200 ml/min, without Ultrasonication, 50 mL Produced)

[0441] First phase solution: HSPC, CHOL, DSPE-PEG2k were co-dissolved in ethanol and filtered with 0.22 m nylon filter membrane. HSPC: CHOL: DSPE-PEG2k=56:38:5 (molar ratio), HSPC concentration: 10 mg/ml.

[0442] Second phase solution: 120 mM ammonium sulfate in water.

[0443] Spray hole diameter at the end of first pipeline D.sub.1(S)=0.25 mm;

[0444] Inner diameter of the second pipeline D.sub.2(IN)=0.8 mm;

[0445] Inner diameter of the combined pipeline D.sub.3(IN)=0.8 mm;

[0446] Outer diameter at the end of first pipeline D.sub.1(O)=0.35 mm;

[0447] Combined phase length=360 mm;

[0448] First phase solution temperature t.sub.1=25 C.;

[0449] Second phase solution temperature t.sub.2=25 C.;

TABLE-US-00037 First phase Second phase ml/min ml/min 10 200

[0450] Calculated based on the fluid in the circular pipeline, the combined phase Re=5505. [0451] The first phase outlet flow velocity is: 3.40 m/s [0452] The second phase flow velocity is: 6.96 m/s [0453] FVR=0.49 [0454] Production quantity: 50 ml

TABLE-US-00038 Average D10 D50 D90 diameter Encapsulation nm nm nm nm D90/D10 efficiency 29 103 1931 66.5 10 131 1226

[0455] The particle size of blank liposomes prepared without ultrasonication showed a distribution with multiple peaks (FIG. 7), and there were large particle size distributions and variances in blank liposomes.

Example 18: Preparation of HSPC/CHOL/DSPE-PEG Blank Liposome (First Phase 10 ml/min, Second Phase 100 ml/min, Under Ultrasonication, 50 mL Produced)

[0456] First phase solution: HSPC, CHOL, DSPE-PEG2k were co-dissolved in ethanol and filtered with 0.22 m nylon filter membrane. HSPC: CHOL: DSPE-PEG2k=56:38:5 (molar ratio), HSPC concentration: 10 mg/ml. [0457] Second phase solution: 120 mM ammonium sulfate in water. [0458] Spray hole diameter at the end of first pipeline D.sub.1(S)=0.25 mm; [0459] Inner diameter of the second pipeline D.sub.2(IN)=0.8 mm; [0460] Inner diameter of the combined pipeline D.sub.3(IN)=0.8 mm; [0461] Outer diameter at the end of first pipeline D.sub.1(O)=0.35 mm; [0462] Combined phase length=360 mm; [0463] First phase solution temperature t.sub.1=25 C.; [0464] Second phase solution temperature t.sub.2=25 C.; [0465] Two phases combine in a 200 W ultrasonic bath

TABLE-US-00039 First phase Second phase ml/min ml/min 10 100

[0466] Calculated based on the fluid in the circular pipeline, the combined phase Re=2884. [0467] The first phase outlet flow velocity is: 3.4 m/s [0468] The second phase flow velocity is: 3.65 m/s [0469] FVR-0.93 [0470] Production quantity: 50 ml

TABLE-US-00040 Average D10 D50 D90 diameter nm nm nm nm D90/D10 107.3 123.7 144.7 131.7 1.35 2.1 3.2 6.7 2.9

[0471] Comparing Examples 22 and 20, for the preparation of blank liposomes under ultrasonication, the particle size shows a distribution with single peak (FIG. 8).

Example 19: Preparation of HSPC/CHOL/DSPE-PEG Blank Liposome (First Phase 10 ml/min, Second Phase 200 ml/min, Under Ultrasonication, 50 mL Produced)

[0472] First phase solution: HSPC, CHOL, DSPE-PEG2k were co-dissolved in ethanol and filtered with 0.22 m nylon filter membrane. HSPC: CHOL: DSPE-PEG2k=56:38:5 (molar ratio), HSPC concentration: 10 mg/ml. [0473] Second phase solution: 120 mM ammonium sulfate in water. [0474] Spray hole diameter at the end of first pipeline D.sub.1 (S)=0.25 mm; [0475] Inner diameter of the second pipeline D.sub.2(IN)=0.8 mm; [0476] Inner diameter of the combined pipeline D.sub.3(IN)=0.8 mm; [0477] Outer diameter at the end of first pipeline D.sub.1(O)=0.35 mm; [0478] Combined phase length=360 mm; [0479] First phase solution temperature t.sub.1=25 C.; [0480] Second phase solution temperature t.sub.2=25 C.; [0481] Two phases combine in a 200 W ultrasonic bath

TABLE-US-00041 First phase Second phase ml/min ml/min 10 200

[0482] Calculated based on the fluid in the circular pipeline, the combined phase Re=5505. [0483] The first phase outlet flow velocity is: 3.40 m/s [0484] The second phase flow velocity is: 6.96 m/s [0485] FVR=0.49 [0486] Production quantity: 50 ml

TABLE-US-00042 Average D10 D50 D90 diameter nm nm nm nm D90/D10 99.5 115.3 138.3 115.3 1.39 0.9 1.1 1.8 1.6

[0487] Comparing Examples 23 and 22, for the preparation of blank liposomes under ultrasonication, when the flow velocity of the second phase increases, the average diameter of the blank liposomes decreases. The particle size shows a distribution with single peak (FIG. 8).

Example 24: Preparation of PTX/HSPC/CHOL/DSPE-PEG Liposome (First Phase 10 ml/min, Second Phase 200 ml/min, Under Ultrasonication, 50 mL Produced)

[0488] First phase solution: PTX, HSPC, CHOL, DSPE-PEG2k were co-dissolved in ethanol and filtered with 0.22 m nylon filter membrane. PTX: HSPC: CHOL: DSPE-PEG2k=9:89:57:4 (molar ratio), HSPC concentration: 10 mg/ml.

[0489] Second phase solution: water. [0490] Spray hole diameter at the end of first pipeline D.sub.1(S)=0.25 mm; [0491] Inner diameter of the second pipeline D.sub.2(IN)=0.8 mm; [0492] Inner diameter of the combined pipeline D.sub.3(IN)=0.8 mm; [0493] Outer diameter at the end of first pipeline D.sub.1(O)=0.35 mm; [0494] Combined phase length=360 mm; [0495] First phase solution temperature t.sub.1=25 C.; [0496] Second phase solution temperature t.sub.2=25 C.; [0497] Two phases combine in a 200 W ultrasonic bath

TABLE-US-00043 First phase Second phase ml/min ml/min 10 200

[0498] Calculated based on the fluid in the circular pipeline, the combined phase Re=5505. [0499] The first phase outlet flow velocity is: 3.40 m/s [0500] The second phase flow velocity is: 6.96 m/s [0501] FVR=0.49 [0502] Production quantity: 50 ml

TABLE-US-00044 Average D10 D50 D90 diameter Encapsulation nm nm nm nm D90/D10 efficiency 45.9 87.3 178.8 81.1 3.89 82.1% 1.7 4.3 10.9 1.7

[0503] Under ultrasonication, PTX liposomes with smaller particle sizes can be prepared, and the particle size shows a distribution with single peak (FIG. 9).

Example 25: Preparation of PTX/PEG-PLA Polymeric Micelle (First Phase 14 ml/min, Second Phase 210 ml/min, without Ultrasonication, 50 mL Produced)

[0504] First phase solution: PTX, PEG-PLA were co-dissolved in acetonitrile, PEG-PLA (50 mg/mL), PTX (15 mg/mL), filtration with 0.22 m nylon filter membrane.

[0505] Second phase solution: water. [0506] Spray hole diameter at the end of first pipeline D.sub.1 (S)=0.25 mm; [0507] Inner diameter of the second pipeline D.sub.2(IN)=0.8 mm; [0508] Inner diameter of the combined pipeline D.sub.3(IN)=0.8 mm; [0509] Outer diameter at the end of first pipeline D.sub.1(O)=0.35 mm; [0510] Combined phase length=360 mm; [0511] First phase solution temperature t.sub.1=25 C.; [0512] Second phase solution temperature t.sub.2=25 C.;

TABLE-US-00045 First phase Second phase ml/min ml/min 14 210

[0513] Calculated based on the fluid in the circular pipeline, the combined phase Re=5872. [0514] The first phase outlet flow velocity is: 4.75 m/s [0515] The second phase flow velocity is: 7.43 m/s [0516] FVR=0.64 [0517] Production quantity: 50 ml [0518] The solution obtained without ultrasonication had more white flocculent precipitate, and the particle size could not be detected.

Example 26: Preparation of PTX/PEG-PLA Polymeric Micelle (First Phase 14 ml/min, Second Phase 210 ml/min, Under Ultrasonication, 50 mL Produced)

[0519] First phase solution: PTX, PEG-PLA were co-dissolved in acetonitrile, PEG-PLA (50 mg/mL), PTX (15 mg/mL), filtration with 0.22 m nylon filter membrane.

[0520] Second phase solution: water. [0521] Spray hole diameter at the end of first pipeline D.sub.1(S)=0.25 mm; [0522] Inner diameter of the second pipeline D.sub.2(IN)=0.8 mm; [0523] Inner diameter of the combined pipeline D.sub.3(IN)=0.8 mm; [0524] Outer diameter at the end of first pipeline D.sub.1(O)=0.35 mm; [0525] Combined phase length=360 mm; [0526] First phase solution temperature t.sub.1=25 C.; [0527] Second phase solution temperature t.sub.2=25 C.; [0528] Two phases combine in a 200 W ultrasonic bath

TABLE-US-00046 First phase Second phase ml/min ml/min 14 210

[0529] Calculated based on the fluid in the circular pipeline, the combined phase Re=5872. [0530] The first phase outlet flow velocity is: 4.75 m/s [0531] The second phase flow velocity is: 7.43 m/s [0532] FVR=0.64 [0533] Production quantity: 50 ml

TABLE-US-00047 D10 D50 D90 Average diameter Encapsulation (nm) (nm) (nm) (nm) PDI efficiency 1 20.4 23.3 26.6 24.9 0.07 85.6% 2 21.2 24.3 28.3 24.9 0.11 86.2% 3 20.3 24.0 30.3 27.1 0.07 85.8%

[0534] As shown in the table, for polymeric nanomicelles prepared under the combined action of shear force and ultrasound, the results of three parallel tests were reproducible and stable.

[0535] Comparing Examples 26 and 25, stable polymeric nanomicelles can be produced under the simultaneous action of ultrasound with conditions that could not form polymeric nanomicelles.

Example 27: Preparation of PTX/PEG-PLA Polymeric Micelle (First Phase 50 ml/min, Second Phase 300 ml/min, Under Ultrasonication, 50 mL Produced)

[0536] First phase solution: PTX, PEG-PLA were co-dissolved in acetonitrile, PEG-PLA (50 mg/mL), PTX (15 mg/mL), filtration with 0.22 m nylon filter membrane.

[0537] Second phase solution: water. [0538] Spray hole diameter at the end of first pipeline D.sub.1(S)=0.25 mm; [0539] Inner diameter of the second pipeline D.sub.2(IN)=0.8 mm; [0540] Inner diameter of the combined pipeline D.sub.3(IN)=0.8 mm; [0541] Outer diameter at the end of first pipeline D.sub.1(O)=0.35 mm; [0542] Combined phase length=360 mm; [0543] First phase solution temperature t.sub.1=25 C.; [0544] Second phase solution temperature t.sub.2=25 C.; [0545] Two phases combine in a 200 W ultrasonic bath

TABLE-US-00048 First phase Second phase ml/min ml/min 50 300

[0546] Calculated based on the fluid in the circular pipeline, the combined phase Re=9176. [0547] The first phase outlet flow velocity is: 17.0 m/s [0548] The second phase flow velocity is: 11.6 m/s [0549] FVR=1.46 [0550] Production quantity: 50 ml

TABLE-US-00049 D10 D50 D90 Average diameter Encapsulation No. (nm) (nm) (nm) (nm) PDI efficiency 1 26.4 48.1 92.7 45.1 0.20 86.0%

[0551] Comparing Examples 26 and 27, it can be found that under the combined action of shear force and ultrasonic, polymeric nanomicelles with smaller particle sizes can also be prepared with different organic solvents and different organic phase flow velocitys, and the polymeric nanomicelles prepared have good stability (FIG. 10).

Example 28: Preparation of PTX/PEG-Phe-PLA Polymeric Micelle (First Phase 14 ml/min, Second Phase 210 ml/min, without Ultrasonication, 50 mL Produced)

[0552] First phase solution: PTX, PEG-Phe-PLA were co-dissolved in acetonitrile, PEG-Phe-PLA (50 mg/mL), PTX (15 mg/mL), filtration with 0.22 m nylon filter membrane.

[0553] Second phase solution: water. [0554] Spray hole diameter at the end of first pipeline D.sub.1(S)=0.25 mm; [0555] Inner diameter of the second pipeline D.sub.2(IN)=0.8 mm; [0556] Inner diameter of the combined pipeline D.sub.3(IN)=0.8 mm; [0557] Outer diameter at the end of first pipeline D.sub.1(O)=0.35 mm; [0558] Combined phase length=360 mm; [0559] First phase solution temperature t.sub.1=25 C.; [0560] Second phase solution temperature t.sub.2=25 C.;

TABLE-US-00050 First phase Second phase ml/min ml/min 14 210

[0561] Calculated based on the fluid in the circular pipeline, the combined phase Re=5872. [0562] The first phase outlet flow velocity is: 4.75 m/s [0563] The second phase flow velocity is: 7.43 m/s [0564] FVR=0.64 [0565] Production quantity: 50 ml

[0566] The solution obtained without ultrasonication had more white flocculent precipitate, and the particle size could not be detected.

Example 29: Preparation of PTX/PEG-Phe-PLA Polymeric Micelle (First Phase 14 ml/min, Second Phase 210 ml/min, Under Ultrasonication, 50 mL Produced)

[0567] First phase solution: PTX, PEG-Phe-PLA were co-dissolved in acetonitrile, PEG-Phe-PLA (50 mg/mL), PTX (15 mg/mL), filtration with 0.22 m nylon filter membrane.

[0568] Second phase solution: water. [0569] Spray hole diameter at the end of first pipeline D.sub.1(S)=0.25 mm; [0570] Inner diameter of the second pipeline D.sub.2(IN)=0.8 mm; [0571] Inner diameter of the combined pipeline D.sub.3(IN)=0.8 mm; [0572] Outer diameter at the end of first pipeline D.sub.1(O)=0.35 mm; [0573] Combined phase length=360 mm; [0574] First phase solution temperature t.sub.1=25 C.; [0575] Second phase solution temperature t.sub.2=25 C.; [0576] Two phases combine in a 200 W ultrasonic bath

TABLE-US-00051 First phase Second phase ml/min ml/min 14 210

[0577] Calculated based on the fluid in the circular pipeline, the combined phase Re=5872. [0578] The first phase outlet flow velocity is: 4.75 m/s [0579] The second phase flow velocity is: 7.43 m/s [0580] FVR=0.64 [0581] Production quantity: 50 ml

TABLE-US-00052 D10 D50 D90 Average diameter Encapsulation (nm) (nm) (nm) (nm) PDI efficiency 1 18.7 21.3 24.3 22.3 0.07 88.2% 2 18.7 21.4 24.4 24.2 0.05 88.8% 3 19.0 21.8 24.8 23.7 0.10 88.5%

[0582] As shown in the table, for polymeric nanomicelles prepared under the combined action of shear force and ultrasound, the results of three parallel tests were reproducible and stable.

[0583] Comparing Examples 29 and 28, stable polymeric nanomicelles can be produced under the simultaneous action of ultrasound with conditions that could not form polymeric nanomicelles.

Example 30: Preparation of PEG-PLA Polymer Nanoparticle (First Phase 50 ml/min, Second Phase 300 ml/min, without Ultrasonication, 50 mL Produced)

[0584] First phase solution: PEG-PLA was dissolved in ethanol, PEG-PLA (50 mg/mL), filtration with 0.22 m nylon filter membrane.

[0585] Second phase solution: water. [0586] Spray hole diameter at the end of first pipeline D.sub.1(S)=0.25 mm; [0587] Inner diameter of the second pipeline D.sub.2(IN)=0.8 mm; [0588] Inner diameter of the combined pipeline D.sub.3(IN)=0.8 mm; [0589] Outer diameter at the end of first pipeline D.sub.1(O)=0.35 mm; [0590] Combined phase length=360 mm; [0591] First phase solution temperature t.sub.1=60 C.; [0592] Second phase solution temperature t.sub.2=60 C.;

TABLE-US-00053 First phase Second phase ml/min ml/min 50 300

[0593] Calculated based on the fluid in the circular pipeline, the combined phase Re=9176. [0594] The first phase outlet flow velocity is: 17.0 m/s [0595] The second phase flow velocity is: 11.6 m/s [0596] FVR=1.46 [0597] Production quantity: 50 ml

TABLE-US-00054 D10 D50 D90 Average diameter Encapsulation No. (nm) (nm) (nm) (nm) PDI efficiency 1 19.09 125.6 263.5 69.5 0.520

Example 31: Preparation of PEG-PLA Polymer Nanoparticle (First Phase 50 ml/min, Second Phase 300 ml/min, Under Ultrasonication, 50 mL Produced)

[0598] First phase solution: PEG-PLA was dissolved in ethanol, PEG-PLA (50 mg/mL), filtration with 0.22 m nylon filter membrane.

[0599] Second phase solution: water. [0600] Spray hole diameter at the end of first pipeline D.sub.1(S)=0.25 mm; [0601] Inner diameter of the second pipeline D.sub.2(IN)=0.8 mm; [0602] Inner diameter of the combined pipeline D.sub.3(IN)=0.8 mm; [0603] Outer diameter at the end of first pipeline D.sub.1(O)=0.35 mm; [0604] Combined phase length=360 mm; [0605] First phase solution temperature t.sub.1=60 C.; [0606] Second phase solution temperature t.sub.2=60 C.; [0607] Two phases combine in a 200 W ultrasonic bath

TABLE-US-00055 First phase Second phase ml/min ml/min 50 300

[0608] Calculated based on the fluid in the circular pipeline, the combined phase Re=9176. [0609] The first phase outlet flow velocity is: 17.0 m/s [0610] The second phase flow velocity is: 11.6 m/s [0611] FVR=1.46 [0612] Production quantity: 50 ml

TABLE-US-00056 D10 D50 D90 Average diameter Encapsulation No. (nm) (nm) (nm) (nm) PDI efficiency 1 16.9 25.5 39.2 25.0 0.152

[0613] It can be seen from the comparison of Example 30 (FIG. 11) and Example 31 (Figure. 12) that the particle size of the nanoparticles obtained without ultrasonic action is larger, and it shows a distribution with multiple peaks, larger polydispersity index and nonuniform in size. However, under the combined action of shear force and ultrasound, the prepared nanoparticles have a smaller particle size, a distribution with single peak, narrow polydispersity index and uniform particle size. These results indicate that the synergistic effect of ultrasound plays an important role in the preparation of nanoparticles with small particle size and narrow distribution.

Example 32: Preparation of PLGA Polymer Nanoparticle (First Phase 50 ml/min, Second Phase 300 ml/min, Under Ultrasonication, 50 mL Produced)

[0614] First phase solution: PLGA was dissolved in ethanol, filtration with 0.22 m nylon filter membrane.

[0615] Second phase solution: water. [0616] Spray hole diameter at the end of first pipeline D.sub.1(S)=0.25 mm; [0617] Inner diameter of the second pipeline D.sub.2(IN)=0.8 mm; [0618] Inner diameter of the combined pipeline D.sub.3(IN)=0.8 mm; [0619] Outer diameter at the end of first pipeline D.sub.1(O)=0.35 mm; [0620] Combined phase length=360 mm; [0621] First phase solution temperature t.sub.1=60 C.; [0622] Second phase solution temperature t.sub.2=60 C.; [0623] Two phases combine in a 200 W ultrasonic bath

TABLE-US-00057 First phase Second phase ml/min ml/min 50 300

[0624] Calculated based on the fluid in the circular pipeline, the combined phase Re-9176. [0625] The first phase outlet flow velocity is: 17.0 m/s [0626] The second phase flow velocity is: 11.6 m/s [0627] FVR=1.46 [0628] Production quantity: 50 ml

TABLE-US-00058 D10 D50 D90 Average diameter Encapsulation No. (nm) (nm) (nm) (nm) PDI efficiency 1 154.1 226.9 337.8 218.5 0.063

[0629] As shown in the table, PLGA polymer nanoparticles can be prepared under the combined action of shear force and ultrasound, and the particle size distribution is narrow with a single peak (FIG. 13).

Example 33: Preparation of PTX/PLGA Polymer Nanoparticle (First Phase 50 ml/min, Second Phase 300 ml/min, Under Ultrasonication, 50 mL Produced)

[0630] First phase solution: PTX and PLGA were dissolved in ethanol, filtration with 0.22 m nylon filter membrane.

[0631] Second phase solution: water. [0632] Spray hole diameter at the end of first pipeline D.sub.1(S)=0.25 mm; [0633] Inner diameter of the second pipeline D.sub.2(IN)=0.8 mm; [0634] Inner diameter of the combined pipeline D.sub.3(IN)=0.8 mm; [0635] Outer diameter at the end of first pipeline D.sub.1(O)=0.35 mm; [0636] Combined phase length=360 mm; [0637] First phase solution temperature t.sub.1=25 C.; [0638] Second phase solution temperature t.sub.2=25 C.; [0639] Two phases combine in a 200 W ultrasonic bath

TABLE-US-00059 First phase Second phase ml/min ml/min 50 300

[0640] Calculated based on the fluid in the circular pipeline, the combined phase Re=9176. [0641] The first phase outlet flow velocity is: 17.0 m/s [0642] The second phase flow velocity is: 11.6 m/s [0643] FVR=1.46 [0644] Production quantity: 50 ml

TABLE-US-00060 D10 D50 D90 Average diameter Encapsulation No. (nm) (nm) (nm) (nm) PDI efficiency 1 165.6 230.9 326.0 225.9 0.027 80.2%

[0645] As shown in the table, PTX/PLGA polymer nanoparticles can be prepared under the combined action of shear force and ultrasound, and the particle size distribution is narrow with a single peak (FIG. 14).

Example 34: Preparation of PolyI Lipid Nanoparticle (First Phase 100 ml/min, Second Phase 200 ml/min, without Ultrasonication, 50 mL Produced)

[0646] First phase solution: 32.31 mg ALC-0315 (CAS #: 2036272-55-4), 4.08 mg DSPE-PEG2000 (CAS #: 147867-65-0), 7.08 mg HSPC (CAS #: 92128-87-5), 14.01 mg cholesterol were dissolved in ethanol, filtration with 0.22 m nylon filter membrane.

[0647] Second phase solution: 5.71 mg PolyI (CAS #: 30918-54-8) in 3 mM citrate buffer solution (pH 4.0). [0648] Spray hole diameter at the end of first pipeline D.sub.1(S)=0.25 mm; [0649] Inner diameter of the second pipeline D.sub.2(IN)=0.8 mm; [0650] Inner diameter of the combined pipeline D.sub.3(IN)=0.8 mm; [0651] Outer diameter at the end of first pipeline D.sub.1(O)=0.35 mm; [0652] Combined phase length=360 mm; [0653] First phase solution temperature t.sub.1=25 C.; [0654] Second phase solution temperature t.sub.2=25 C.;

TABLE-US-00061 First phase Second phase ml/min ml/min 100 200

[0655] Calculated based on the fluid in the circular pipeline, the combined phase Re=7865. [0656] The first phase outlet flow velocity is: 34.0 m/s [0657] The second phase flow velocity is: 9.94 m/s [0658] FVR=3.4 [0659] Production quantity: 50 ml

TABLE-US-00062 D10 D50 D90 Average diameter Encapsulation No. (nm) (nm) (nm) (nm) PDI efficiency 1 42.6 84.7 624.8 89.6 0.41 35.3%

[0660] PolyI lipid nanoparticles prepared without ultrasonication shows a distribution with multiple peaks (FIG. 15) and has low encapsulation efficiency.

Example 35: Preparation of PolyI Lipid Nanoparticle (First Phase 100 ml/min, Second Phase 200 ml/min, Under Ultrasonication, 50 mL Produced)

[0661] First phase solution: 32.31 mg ALC-0315, 4.08 mg DSPE-PEG2000, 7.08 mg HSPC, 14.01 mg cholesterol were dissolved in ethanol, filtration with 0.22 m nylon filter membrane. Second phase solution: 5.71 mg PolyI in 3 mM citric acid buffer (pH 4.0). [0662] Spray hole diameter at the end of first pipeline D.sub.1(S)=0.25 mm; [0663] Inner diameter of the second pipeline D.sub.2(IN)=0.8 mm; [0664] Inner diameter of the combined pipeline D.sub.3(IN)=0.8 mm; [0665] Outer diameter at the end of first pipeline D.sub.1(O)=0.35 mm; [0666] Combined phase length=360 mm; [0667] First phase solution temperature t.sub.1=25 C.; [0668] Second phase solution temperature t.sub.2=25 C.; [0669] Two phases combine in a 200 W ultrasonic bath

TABLE-US-00063 First phase Second phase ml/min ml/min 100 200

[0670] Calculated based on the fluid in the circular pipeline, the combined phase Re=7865. [0671] The first phase outlet flow velocity is: 34.0 m/s [0672] The second phase flow velocity is: 9.94 m/s [0673] FVR=3.4 [0674] Production quantity: 50 ml

TABLE-US-00064 D10 D50 D90 Average diameter Encapsulation No. (nm) (nm) (nm) (nm) PDI efficiency 1 53.9 83.5 133.3 85.7 0.21 78.9%

[0675] As shown in the table, the PolyI lipid nanoparticle prepared under the combined action of shear force and ultrasonication showed a distribution with a single peak (FIG. 16), narrow particle size distribution and high encapsulation efficiency.

Comparative Example 1: Preparation of SN-38/ICG Nanoparticle (Mixing Followed by Ultrasound)

[0676] First phase solution: ICG and SN-38 were dissolved in DMSO, SN-38 content: 3.394 wt. %, ICG content: 3.397 wt. %, SN-38 to ICG molar ratio was 2:1, filtration with 0.22 m nylon filter membrane. [0677] Second phase solution: water [0678] Spray hole diameter at the end of first pipeline D.sub.1(S)=0.6 mm; [0679] Inner diameter of the second pipeline D.sub.2(IN)=5.4 mm; [0680] Inner diameter of the combined pipeline D.sub.3(IN)=5.4 mm; [0681] Outer diameter at the end of first pipeline D.sub.1(O)=2 mm; [0682] Outer diameter of the second pipeline D.sub.2(O)=6 mm; [0683] Outer diameter of the combined pipeline D.sub.3(O)=6 mm; [0684] Combined phase length=90 mm; [0685] First phase solution temperature t.sub.1=25 C.; [0686] Second phase solution temperature t.sub.2=25 C.; [0687] Two phases combine in a 200 W ultrasonic bath

TABLE-US-00065 First phase Second phase ml/min ml/min 11 193

[0688] Calculated based on the fluid in the circular pipeline, the combined phase Re-747, with SK type static mixer, static mixer size: 5.3 mm*85 mm, with a total of 16 repeating spiral plates. [0689] The first phase outlet flow velocity is: 0.648 m/s [0690] The combined phase flow velocity is: 0.148 m/s [0691] FVR=4.4 [0692] Production quantity: 20 ml

[0693] The solutions were mixed first according to the above conditions, and the resulting mixture was sonicated for 10 minutes (ultrasonic power: 200 W, ultrasonic temperature 25 C.)

TABLE-US-00066 Average Filtration D10 D50 D90 diameter encapsulation Ultrasound (nm) (nm) (nm) (nm) PDI efficiency (SN-38) mixing followed 36.7 5.6 162.8 10.7 272.8 55.0 141.6 16.8 0.443 0.089 53.2% by ultrasonication

[0694] Compared with (2) in Example 4, the particle size of the nanoparticles is slightly reduced, but the encapsulation efficiency cannot be improved.

Comparative Example 2: Preparation of SN-38/ICG Nanoparticle (Ultrasonication Only)

[0695] Solution A: ICG and SN-38 were dissolved in DMSO, SN-38 content: 3.394 wt. %, ICG content: 3.397 wt. %, SN-38 to ICG molar ratio was 2:1, filtration with 0.22 m nylon filter membrane.

[0696] 45 ml of water was added to the flask, 5 ml of solution A was added under ultrasonication (ultrasonic power 200 W), and was sonicated at 25 C. for 10 minutes. The resulting mixture has a lot of flocculent precipitate, the particle size can not be detected, and nanoparticles cannot be formed.

Comparative Example 3: Preparation of SN-38/ICG Nanoparticle (Ultrasonication First, then Mix Through a Mixer)

[0697] Solution A: ICG and SN-38 were dissolved in DMSO, SN-38 content: 3.394 wt. %, ICG content: 3.397 wt. %, SN-38 to ICG molar ratio was 2:1, filtration with 0.22 m nylon filter membrane.

[0698] 45 ml of water was added to the flask, 5 ml of solution A was added under ultrasonication (ultrasonic power 200 W), and was sonicated at 25 C. for 10 minutes. The resulting mixture has a lot of flocculent precipitate. The mixture was mixed through mixer following conditions of (2) in Example 4, resulting in a cloudy mixture, and nanoparticles cannot be formed. The particle size can not be detected. The pipelines were blocked.

[0699] Although the specific embodiments of the present invention have been described above, those skilled in the art should understand that these are only illustrations, and that various changes or modifications may be made to these embodiments without deviating from the principle and substance of the present invention. Therefore, the scope of protection of the present invention is limited by the attached claims.